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Abstract
Obesity is a constantly increasing health burden affecting more than 30% of the
population of westernized countries. In addition to classical associated disorders,
obesity was also previously reported to increase the incidence of hepatocellular
carcinoma (HCC) development, in part through activation of obesity-associated
pro-inflammatory signaling and the release of inflammatory cytokines such as
TNFα and IL-6, both known as tumor-promoting cytokines. Nevertheless, how
these inflammatory cytokines trigger HCC development is currently not fully un-
derstood.
The current work reports that abrogation of IL-6Rα signaling in lean mice pro-
tects against DEN-induced HCC development. This HCC protection occurs via
destabilization of anti-apoptotic Bcl-2 family member Mcl-1, thus promoting hep-
atocyte apoptosis. In lean mice IL-6 regulates the stability of Mcl-1 via inhibi-
tion of PP-1α expression which promotes GSK-3β inactivation by serine 9 residue
phosphorylation. In addition, IL-6 suppresses expression of the Mcl-1 E3 ligase
Mule. Consequently, IL-6Rα deficiency activates PP1-α and Mule expression re-
sulting in increased Mcl-1 turnover and protection against HCC development. In
contrast, in obese mice inhibition of PP1-α and Mule expression leading to Mcl-1
stabilization occurs independent from IL-6 signaling.
Furthermore, the current work could demonstrate that IL-6Rα signaling in T
cells is essential for the development of HCC indicated by the protective effect of
IL-6Rα deficiency on T cells.
Collectively, this study provides evidence that IL-6 and obesity inhibit hepato-
cyte apoptosis through Mcl-1 stabilization thus promoting liver carcinogenesis.
Zusammenfassung
Adipositas ist ein konstant wachsendes Gesundheitsproblem, welches schon heute
mehr als 30% der westlichen Bevölkerung betrifft. Zusätzlich zu den klassisch-
assoziierten Krankheiten, erhöht Adipositas auch die Gefahr der hepatozellulärer
Karzinomentwicklung (HCC). Dies geschieht teilweise durch Aktivierung von
Adipositas-assoziierten Signalwegen, welche zur Freisetzung von tumorfördern-
den, inflammatorischen Zytokinen wie TNFα und IL-6 führen. Unbekannt ist
jedoch wie diese Zytokine die Entwicklung von HCC auslösen. Die vorliegende
Arbeit zeigt, dass die Inaktivierung des IL6Rα normalgewichtige Mäusen vor der
DEN induzierte HCC Entwicklung schützt. Durch die Destabilisierung von Mcl-
1, einem Mitglied der Anti-apoptotischen Bcl-2 Familie, wird die Apoptose in
Hepatozyten gefördert. Dies schützt die Leber vor der Entwicklung von HCC.
In normalgewichtigen Mäusen reguliert IL-6 die Stabilität von Mcl-1 durch Hem-
mung der PP-1α Expression, welches wiederum die Inaktivierung von GSK-3β
fördert. Zusätzlich unterdrückt IL-6 die Expression der Mcl-1 ubiquitin ligase E3
Mule. In IL-6Rα defizienten Mäusen wird die Expression von PP-1α und Mule
aktiviert, dies führt zu einem erhöhten Umsatz von Mcl-1 und zum Ausbleiben
von HCC. Im Gegensatz dazu führt bei Adipositas die Hemmung der PP-1α und
Mule Expression zu einer Stabilisierung von Mcl-1, unabhängig von der IL-6 Sig-
nalübertragung. Desweiteren kann mit der vorliegenden Arbeit gezeigt werden,
dass die IL-6Rα-signalübertragung in T Zellen essentiell für die Entwicklung von
HCC ist. Hinweise dafür liefert der schützende Effekt der IL-6Rα-defizienz auf
T Zellen. Insgesamt liefert diese Studie Beweise dafür, dass IL-6 und Adiposi-
tas die Apoptose in Hepatozyten durch Mcl-1 Stabilisierung hemmen und so die
Leberkarzinogenese fördern.
1 Introduction
1.1 Hepatocellular carcinoma
Cancer is a general term for a large group of diseases that can occur in almost
every part of the body. Cancer development is characterized by uncontrolled cell
growth that leads to tumor formation and invasion of these cells to neighboring
tissues [Croce, 2008]. Cancer is a disease which is more frequent in older ages.
Due to an increase in the old population, the World Health Organisation (WHO)
assumes an increase in the cancer-related mortality rate from 7.9 million (2007) to
11.5 million (2030) cases per year. In most industrialized countries, cancer is the
second most frequent cause of death after cardiovascular diseases [Alwan, 2011].
Hepatocellular carcinoma (HCC) is the third most common cancer worldwide
(Fig. 1.1A) and represents, with 85-90% of all primary liver cancers, the most
common one [El-Serag & Rudolph, 2007]. The average mortality is 95% within 5
years due to limited treatment strategies and the late exhibition of clinical symp-
toms [Sherman, 2005; Villanueva et al., 2010]. Therefore, HCC represents the third
largest cause of cancer deaths worldwide, especially for men in low- and middle-
income countries, such as Africa and Eastern Asia (Fig. 1.1B). Male individuals
have a 4-fold increase in HCC incidence compared to women. These results could
be confirmed by Maria et al. [2002] in mouse models. Accordingly, females have
a lower incidence for HCC due to an estrogen-dependent mechanism [Naugler
et al., 2007]. However, the increasing incidence of HCC in industrialized countries
cannot be neglected [El-Serag et al., 2003].
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Figure 1.1: Cancer distribution and HCC incidence rates worldwide in 2011
(A) Worldwide distribution of different cancer forms of both genders in per-
centage of total cancer numbers from 2011. (WHO globocan project) (B) Dis-
tribution of HCC incidence in 2011 (ASR per 100000). (WHO globocan project)
Cancer development and progression is influenced by genetic, epigenetic and
environmental factors. HCC is linked to a variety of genetic predispositions, such
as mutations in tumor suppressor genes, as well as to viral infections such as
hepatitis B (HBC) or C (HCV), alcoholic liver disease, hemochromatosis and non-
alcoholic steatohepatitis [Villanueva et al., 2007; Fattovich et al., 2004; Yoshioka
et al., 2004; Thorgeirsson & Grisham, 2002; Donato et al., 2002; Yu et al., 2001].
All of which cause liver damage and chronic inflammation and therefore pro-
mote HCC, which is characterized as a classic case of inflammation-linked can-
cer [Sanz-Cameno et al., 2010; Mantovani et al., 2008; Karin et al., 2006; Karin &
Greten, 2005; Balkwill & Mantovani, 2001].
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1.1.1 Linking inflammation to HCC
Human studies could demonstrate that chronic inflammation in alcoholic hep-
atitis, HBV and HCV infections and steatohepatitis may lead to development of
HCC [Abiru et al., 2006; Sherman, 2005]. Even in mouse studies a strong correla-
tion could be exhibit between the amount of liver damage during acute toxicity
and inflammation and the extent of HCC development [Naugler et al., 2007; Saku-
rai et al., 2006; Maeda et al., 2005]. Furthermore, Maeda and others could demon-
strate that chemically or genetically induced HCC depends on inflammatory sig-
naling [Sakurai et al., 2006; Maeda et al., 2005; Pikarsky et al., 2004]. Liver injury
and chronic inflammation that results in compensatory proliferation of differen-
tiated hepatocytes, which are otherwise quiescent, is one of the major pathogenic
mechanisms underlying HCC development [Sakurai et al., 2006; Fausto, 1999;
Maeda et al., 2005]. The relevance of compensatory proliferation as a tumori-
genic mechanism is supported by mouse genetic studies, using either the hepatic
pro-carcinogen Diethylnitrosamine (DEN) as an inducer of HCC [Hui et al., 2008;
Sakurai et al., 2006; Maeda et al., 2005] or the conditional or complete inactiva-
tion of nuclear factor ’kappa light chain enhancer’ of activated B cells (NF-κB)
signaling, needed for maintenance of hepatocyte survival [Luedde et al., 2007].
The resulting necrosis of hepatocytes in these studies enhances mutagenesis in
host cells, accumulation of double strand breaks and results in HCC [Karin, 2008;
Sakurai et al., 2006; Maeda et al., 2005]. Furthermore, during chronic inflammation
the infiltrating immune cells create a tumor microenvironment releasing elevated
levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFα)
and Interleukin 6 (IL-6) [Newell et al., 2008; Xu et al., 2003]. Liver injury and com-
pensatory proliferation are strongly depending on IL-6 and the absence of this
cytokine results in almost complete inhibition of DEN-induced HCC [Naugler
et al., 2007]. Furthermore, IL-6 deficient mice demonstrate reduced liver injury,
apoptosis, necrosis and proliferation in hepatocytes after DEN-injection, charac-
terizing inflammation as the major contributing factor in HCC development.
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1.2 Linking obesity to HCC
Previous epidemiological studies identified obesity as a major risk factor for sev-
eral cancer entities and demonstrated a 1.52 - 1.62-fold increase in relative risk
of cancer related death [Calle et al., 2003; Calle & Kaaks, 2004; Bianchini et al.,
2002]. The amount of increase in risk depends on the type of cancer, whereas
HCC exhibited the strongest obesity-associated increase in tumor incidence with
a 4.52-fold increase, particularly in men with a body mass index over 35 (Fig. 1.2)
[Calle et al., 2003]. Thus, the obesity-associated increase in HCC development
gains substantial clinical relevance in the light of the current epidemical increase
in obesity in westernized societies [Ford & Mokdad, 2008].
Figure 1.2: Mortality from Cancer According to Body-Mass Index for U.S. Men in the
Cancer Prevention Study
For each relative risk, comparison between men in highest BMI category (in-
dicated in parentheses) and men in reference category (BMI, 18.5 to 24.9). As-
terisks indicate relative risks for men who never smoked. Results were signif-
icant (p ≤ 0.05) for all cancer sites. [Calle et al., 2003]
Obesity is a constantly increasing health burden affecting more than 30% of
the population of westernized countries. Obesity is defined as a condition of ab-
normal or excessive body fat accumulation that is a consequence of a sustained
positive energy balance. That means consuming more calories than spending,
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resulting in excessive storage of lipids in the adipose tissue. A more sedentary
lifestyle in western societies with reduced physical work and the increased avail-
ability of food due to the industrialization contributes further to a positive energy
balance.
In 2008, approximately 1.5 billion adults were overweight, of which over 200
million men and approximately 300 million women were obese. Following record-
ings of each country in the WHO European Region from 2008, over 50% of both
men and women have a body mass index (BMI = weight in kilograms / size in
meters2) higher than 25 and thus considered to be overweight. Nearly 23% of
these were obese indicated by a BMI above 30 (Fig. 1.3 [Berghofer, 2008].
A B
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Figure 1.3: Prevalence of obesity in adults from 2001 and 2010
The worldwide prevalence of obese adults (BMI >30) compared from 2001 and
2010. Datas were obtained from the WHO.
The association between fat accumulation and HCC was known for a long time
[El-Serag & Rudolph, 2007; Caldwell et al., 2004]. Fatty liver disease (FLD) turned
out to be one of the major risk factors for HCC which rapidly increased over the
last years in western countries. Obesity and FLD lead to steatosis and cirrhosis
and thereby increase the incidence of HCC [Yoshioka et al., 2004; Calle et al., 2003].
While the current study was being completed, Park et al. [2010] could demon-
strate that genetically and dietary-induced obesity enhances development of chem-
ically induced HCC. Moreover, earlier studies described that consumption of
high fat diet (HFD) resulted in increased formation of pre-neoplastic lesions in
response to DEN administration in rats [Wang et al., 2009]. However, these rats
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were not evaluated for HCC and the mechanism underlying increased formation
of the lesions was not determined.
Another recent study used mice with hepatocyte-specific deficiency of the reg-
ulatory subunit NF-κB essential modulator (NEMO) of the inhibitor of kappa B
kinase (IKK) complex or the IKKs itself (Nemo/IKKγ∆hep), which spontaneously
develop liver damage, hepatosteatosis and HCC on a normal chow diet (NCD)
[Luedde et al., 2007]. These mice revealed enhanced development of hepatosteato-
sis and liver damage after HFD-feeding, which ultimately results in accelerated
tumor development in the liver [Wunderlich et al., 2008]. However, the pre-
existing hepatosteatosis and spontaneous liver damage in Nemo/IKKγ∆hep mice
upon NCD feeding prevented the conclusive demonstration that obesity per se
rather than chronic liver damage, caused by the absence of NF-κB, is responsible
for tumor promotion. Furthermore, the mechanism by which obesity accelerates
HCC development in these mice was not determined.
1.2.1 Linking chronic low grade inflammation in obesity to HCC
The excessive weight gain during obesity is associated with a chronic low grade
inflammatory state. The concept of chronic low grade inflammation in response
to obesity was first demonstrated by elevated expression of TNFα in the white
adipose tissue (WAT) [Hotamisligil et al., 1993]. Follow-up studies confirmed the
observation in humans, where WAT also expresses increased TNFα upon obesity,
which was decreased after weight loss [Gonzalez et al., 1999; Dandona et al., 1998;
Hotamisligil et al., 1995; Kern et al., 1995]. Additional work demonstrated that
the chronic low grade inflammation in obesity is not only locally in WAT, but also
systemically, indicated by elevated plasma concentrations of circulating TNFα
and IL-6 [Nishimura et al., 2009; Xu et al., 2003; Bastard et al., 2000; Mohamed-Ali
et al., 1997; Hotamisligil et al., 1993]. During the development of obesity, immune
cells, such as macrophages and T cells, infiltrate tissues, such as WAT or liver,
and lead to increased secretion of TNFα and IL-6 [Nishimura et al., 2009; Xu et al.,
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2003]. The tumor promoting effect of HFD depends to a large extent on this el-
evated levels of TNFα and IL-6, both of which are tumor-promoting cytokines
[Park et al., 2010; Lin & Karin, 2007].
Liver injury and compensatory proliferation are strongly depending on IL-6
and the absence of this cytokine results in almost complete inhibition of DEN-
induced HCC [Naugler et al., 2007]. Additionally, it could be demonstrated that
obesity increases IL-6 level compared to lean mice and thereby accelerates tumor
development [Park et al., 2010]. IL-6 may not be the only mediator responsible for
obesity-induced cancer promotion, however, it is well established that its produc-
tion is elevated in obese mice due to the low-grade inflammatory response caused
by lipid accumulation [Arkan et al., 2005; Shoelson et al., 2007; Solinas et al., 2007;
Hotamisligil, 2006].
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1.3 Interleukin 6 signaling pathway
IL-6 is a pleiotropic cytokine largely responsible for the hepatic response to in-
fections or systemic inflammation, often termed the "acute phase response". IL-
6 regulates activation of phagocytosis and acute phase proteins such as the c-
reactive protein or serum amyloid A in the inflammation process [Barton, 1996].
Moreover, IL-6 plays a key role in the transition from innate to adaptive immu-
nity by initiating differentiation of T- and B-lymphocytes [Brooks et al., 1985].
The IL-6 gene consists of 5 exons whose expression results in an inactive pre-
peptide of 212 amino acids which is then cleaved into the active form of 184 amino
acids. IL-6 has several splice forms and is posttranslationally modified by gly-
colisation and phosphorylation [Parekh et al., 1992]. The membrane bound IL-6
receptor (IL-6R) is expressed on hepatocytes, macrophages, T lymphocytes and
endothelial cells [Barton, 1996]. The heterotrimeric receptor consists of two signal
transduction β-chains glycoprotein 130 (gp130) and one IL-6R α-chains. Gp130 is
widely used by a cohort of cytokines receptors, especially by the IL-6 type cy-
tokine receptor family including Interleukin 11 receptor (IL-11R), oncostatin M
receptor (OSMR), ciliary neurotrophic factor receptor (CNTFR), Interleukin 27
receptor (IL-27R), Epstein-Barr virus induced gene 3 (EBI-3) and leukemia in-
hibitory factor receptor (LIFR) [Zhang et al., 1994]. In contrast the IL-6Rα chain
is specific for IL-6 signaling in hepatocytes, macrophages, endothelial cells and
T-lymphocytes [Hibi et al., 1996].
Besides the classical membrane bound IL-6 receptor signaling an alternative
pathway exists using a soluble form of the IL-6 receptor (sIL-6Rα). The sIL-6Rα is
either created by shedding of the extracellular part of the membrane bound IL-6
receptor which is triggered by the c-reactive protein or is produced by alternative
splicing of the messenger RNA (mRNA) [Jones et al., 1999]. A complex of IL-6
and the sIL-6Rα can bind to the gp130 signaling chain at virtually all cell types,
thereby rendering also cells responsible to IL-6 which do not express the IL-6Rα
chain [Graeve et al., 1996]. This kind of IL-6 signaling was described as “transsig-
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naling” which can be inhibited by soluble gp130 (sgp130) [Chalaris et al., 2007].
IL-6 expression is regulated by TNFα signaling which activates a dual kinase
system (Fig. 1.4). On the one hand, TNFα leads to survival which is mediated by
the IKK kinases phosphorylating the inhibitor of NF-κB (IκBα), thus, liberating
NF-κB transcription factors to induce IL-6 transcription and proliferation [Karin,
2008]. On the other hand, TNFα induced apoptosis as a consequence of c-Jun N
terminal kinase (JNK) activation phosphorylating the classical activated protein
1 (AP-1) [Karin & Gallagher, 2005; Ventura et al., 2003].
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Figure 1.4: TNFα signaling pathway
TNFα binds to its receptor and mediates signaling by the IKK complex (IKK1,
IKK2, NEMO). The IKK complex phosphorylates IκB leading to its ubiquiti-
nation and degradation by the proteasome. The transcription factor NF-κB
translocates to the nucleus and activates transcription of target genes such as
IL-6. Alternatively, the TNFα receptor phosphorylates MAP3K mediated by
Caspase 8 leading to phosphorylation of MKK which results in JNK activa-
tion. c-Jun, phosphorylated by JNK forms AP-1 with the JunB proteins and
regulates target genes.
1 Introduction 10
1.3.1 JAK/Stat-signaling
Upon IL-6 binding to the IL-6Rα, the gp130 complex recruits Janus-activated-
kinases (JAK) [O’Shea et al., 2002]. JAKs provide tyrosine kinase activity at the
activated IL-6Rα. These JAKs bind to the intracellular receptor domains and
phosphorylate tyrosines of the IL-6Rα after JAK dimers phosphorylate each other
[O’Shea et al., 2002]. These phosphorylated tyrosines of the receptor are binding
sites for proteins containing src- homology 2 (SH2) domains [O’Shea et al., 2002].
Signal transducer and activator of transcription 3 (Stat-3) binds to the receptor by
its SH2 domain and thereby tyrosin 705 of Stat-3 is phosphorylated by the JAKs
[O’Shea et al., 2002]. This induces a conformational change and creates new SH2
binding sites at the Stat-3 surface [Akira, 1997]. Therefore, Stat-3 dissociates from
the IL-6Rα, forms homodimers, translocates into the nucleus and enhances or in-
hibits transcription of target genes (Fig. 1.5) [Ramadori & Christ, 1999; Akira,
1997].
One of the target genes of Stat-3 is the suppressor of cytokine signaling (Socs)
3 [Endo et al., 1997]. Socs-3 in turn negatively regulates the IL-6 mediated sig-
naling transduction pathway in a negative feedback loop (Fig. 1.5). On the one
hand, Socs-3 binds to phosphorylated tyrosine at the IL-6Rα and therefore occu-
pies binding sites for Stat-3. On the other hand, Socs-3 binds directly to JAKs
thereby reducing JAK kinase activity [Kawazoe et al., 2001; Naka et al., 1999, 1997;
Bjørbaek et al., 1998; Endo et al., 1997].
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Figure 1.5: IL-6 signaling pathway
IL-6 binds to its receptor, composed of gp130 and IL6Rα. Gp130 recruits JAKs
which phosphorylate the receptor after transphosphorylation. The phospho-
rylated receptor recruits Stat-3 which is phosphorylated by JAKs and forms
homodimers. These dimers translocate to the nucleus and induce transcrip-
tion of target genes.
1.3.2 MAPK-signaling
Additionally to the JAK/Stat pathway, IL-6 activates the mitogen-activated pro-
tein kinase (MAPK) pathway (Fig. 1.5). The MAPK pathway regulates embryonic
development, cell differentiation, cell proliferation and apoptosis and is activated
by mitogenes, cytokines or cellular stress [Davis et al., 2002; Davis, 2000]. Three
groups of MAPK are described consisting of JNK, the extracellular signal-related
kinases (ERK) and the p38 protein kinases (Fig. 1.5) [Ramadori & Christ, 1999].
JNK is mainly activated by pro-inflammatory cytokines such as TNFα and IL-6
or by cellular stress [Weston & Davis, 2002]. The signal transduction from the
receptor to the MAP3K is not yet fully elucidated. However, it was demonstrated
1 Introduction 12
that mixed-lineage protein kinase (MLK) 1, apoptosis signal-regulating kinase
(ASK) 1, MAP kinse-ERK kinase (MEK) 1/4, TGF activated kinase (TAK) 1 and
JNK 1-3 are participating in this signaling pathway [Davis, 2000; Baud et al., 1999].
Finally, JNK phosphorylates c-Jun which forms a homodimer or heterodimer
with other Jun- or FBJ osteosarcoma oncogene- (Fos) proteins to produce AP-1
[Weston & Davis, 2002; Karin & Chang, 2001]. AP-1 activation regulates cytokine
production, enhances transcription of mitotic genes such as Cyclin D1 and re-
duces expression of cell cycle arrest genes such as p53 [Angel & Karin, 1991].
The ERK signaling pathway involves MEK 1 and 2, rapidly accelerated fi-
brosarcoma kinase (RAF) and ERK 1 and 2 and regulates cell growth, prolifer-
ation and differentiation [Zhang et al., 2004]. Over-expression and activation of
ERK can be detected in many types of cancer [Jin et al., 2013; Bartholomeusz et al.,
2012; Caja et al., 2009; Zhang et al., 2004].
The p38 pathway is activated by stress, UV light and osmotic stress. This path-
way involves signaling of MLK and ASK-1 as well as TAK, McKusick-Kaufman
syndrome kinase (MKK) 3/6, p38 and MAPKα/β and results in similar outcomes
as the ERK pathway [Shi & Gaestel, 2002; Tibbles & Woodgett, 1999].
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1.4 Apoptosis
Evading or inhibiting apoptosis is one of the hallmarks in the development of
cancer [Hanahan & Weinberg, 2000]. The hypothesis that apoptosis serves as a
barrier to cancer was first raised in 1972, when Kerr, Wyllie, and Currie described
massive apoptosis in the cells populating rapidly growing, hormone-dependent
tumors following hormone withdrawal [Kerr et al., 1972].
Apoptosis is the process of programmed cell death and can be induced by sev-
eral stimuli including cellular stress, UV-light, DNA damage and virus infections
[Green, 2005]. Apoptosis leads to characteristic morphological cell changes, in-
cluding cell shrinkage, nuclear fragmentation, chromatin condensation and chro-
mosomal DNA fragmentation, which subsequently results in cell death [Hanahan
& Weinberg, 2011]. In contrast to necrosis, which is a form of traumatic cell death,
apoptosis is necessary during an organism’s life cycle, for example for the separa-
tion of fingers and toes in a developing human embryo [Haruta et al., 2011]. Fur-
thermore, apoptosis is necessary to eliminate cells with DNA damage and keeps
proliferating tissue in balance [Hanahan & Weinberg, 2011]. Missregulation of
apoptosis results in wide range of pathophysiological consequences, including
carcinogenesis and Alzheimer’s disease [Rohn, 2010]. The apoptotic process is
tightly regulated and divided into two pathways which can overlap. On the one
hand the extrinsic pathway mediated by membrane-bound death receptors, such
as the TNF-receptor, on the other hand the intrinsic pathway mediated intracel-
lular via the mitochondria [Hanahan & Weinberg, 2011].
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1.4.1 Extrinsic apoptotic pathway
The extrinsic apoptotic pathway is mediated via death receptors (DR) from the
TNF-receptor family, including Fas (CD95/Apo1), TNFR, DR3, DR4, DR5, DR6,
NGFR and EDAR [Bhardwaj & Aggarwal, 2003] . After binding of the ligand at
the extracellular, cystein-rich part of the DR, adapter proteins are recruited to the
intracellular part of the receptor which cleaves and thereby activates Caspase 8
(Fig. 1.6A) [Hengartner, 2000]. This leads to recruitment of Caspase 3. Caspase
3 is cleaved by Caspase 9 and thereby activated which results in degradation of
cellular components (Fig. 1.6A) [Malhi et al., 2010].
1.4.2 Intrinsic apoptotic pathway
The key element of the intrinsic apoptotic pathway are the mitochondria which
are the central sensory organelle that can respond to DNA damage. The double
membrane of the mitochondria consists of the inner and the outer membrane. The
inner, impermeable mitochondrial membrane (IMM) consists of many invagina-
tions called cristae and harbor different enzyme complexes essential for the respi-
ratory chain. The outer, semi-permeable mitochondrial membrane (OMM) com-
prises different membrane-bound protein complexes which allow the exchange of
small molecules and proteins between mitochondria and cytosol. The intermem-
brane space (IMS) contains pro-apoptotic factors such as cytochrome C, apoptosis
inducing factor (AIF) or endonuclease G which cannot pass through the constitu-
tive protein channel and stay in the IMS. (Fig. 1.6B) The mitochondria respond to
DNA damage by mitochondrial outer membrane permeabilization [Green, 2005;
Chipuk et al., 2006]. By forming pores, cytochrome C can be released into the cyto-
plasm and interact with apoptotic protease activating factor-1 (Apaf-1) (Fig. 1.6C)
[Green, 2005; Chipuk et al., 2006]. Recruitment of pro-Caspase 9 to the complex
then leads to formation of the apoptosom, cleavage of Caspase 9 and activation
of Caspase 3 (Fig. 1.6C) [Green, 2005; Chipuk et al., 2006].
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Figure 1.6: Apoptotic pathway
(A) After stimulation by extrinsic signals adapter proteins are recruited to the
receptor, Caspase 8 is recruited and activated which results in cleavage and
thereby activation of Caspase 3. (B) In the physiological state Mcl-1 exists in a
complex with Bak associated with the OMM. (C) After cytotoxic stimuli Mcl-1
is separated from Bak by active BH3-only proteins, phosphorylated, ubiquiti-
nated by Mule and degraded by the proteasome. Bak and Bax can oligomerise
and integrate in the OMM to form pores which leads to the release of cy-
tochrome C. Cytochrome C interacts with Apaf-1 and recruits Caspase 9 to
form the apoptosom which leads to cleavage and activation of Caspase 3. (C)
The intrinsic pathway can be activated via extracellular signals by Bid. Cas-
pase 8, activated via DR signaling, can cleave Bid and the resulting truncated
Bid (tBid) interacts with Bax and leads to the integration in the OMM.
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1.4.3 B-cell lymphoma (Bcl-2) family
The balance between anti- and pro-apoptotic members of the Bcl-2 protein fam-
ily regulates mitochondrial outer membrane permeabilization and the efflux of
cytochrome C in response to cellular damage [Brunelle & Letai, 2009]. The Bcl-2
protein family consists of pro-apoptotic proteins such Bcl-2 homologues antago-
nist/killer (Bak) and Bcl-2-associated X protein (Bax) and anti-apoptotic proteins
such as Bcl-2, Bcl-XL and Myeloid leukemia cell 1 (Mcl-1). Another sub-group
consists of the pro-apoptotic BH3-only proteins such as p53 upregulated modu-
lator of apoptosis (Puma) and phorbol-12-myristate-13-acetate-induced protein 1
(PMAIP1), also known as Noxa, which have only one of the four Bcl-2 homology
domains [Thomas et al., 2010]. These proteins promote apoptosis by binding at
anti-apoptotic proteins [Brinkmann et al., 2013; Eskes et al., 2000].
Bax and Bak are constitutively expressed. Bak is associated with the OMM
whereas Bax is located in the cytosol (Fig. 1.6C). After initiation of apoptosis,
Bim binds at Bax which leads to a conformational change and to translocation
to the OMM (Fig. 1.6C) [Ren et al., 2010]. Bax oligomerise with Bak, integrates
into the OMM and creates pores which leads to the release of cytochrome C (Fig.
1.6C) [Malhi et al., 2010].
To avoid a constitutive activation of apoptosis, anti-apoptotic proteins are bound
to Bax and Bak to suppress membrane permeabilization. Bak is bound by Mcl-1
at the OMM which can be detached via replacement by Noxa (Fig. 1.6C) [Ren
et al., 2010]. After phosphorylation Mcl-1 is ubiquitinated by the Mcl-1 ubiquitin
ligase E3 (Mule) and degraded by the proteasome [Zhong et al., 2005].
The extrinsic and intrinsic apoptotic pathway are conected via BH3 interacting-
domain death agonist (Bid). Caspase 8, activated via death receptor signaling, can
cleave Bid and the resulting truncated Bid (tBid) interacts with Bax and leads to
integration in the OMM (Fig. 1.6D) [Eskes et al., 2000].
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1.4.4 Missregulation of apoptosis in cancer
The discovery of the upregulation of the Bcl-2 oncogene in follicular lymphoma
[Korsmeyer, 1992] and its recognition as having anti-apoptotic activity opened up
the investigation of apoptosis in cancer at the molecular level [Vaux et al., 1988].
Further insights into the myc-Bcl-2 interaction emerged later from studying the
effects of a myc oncogene on fibroblasts cultured under low serum conditions.
Widespread apoptosis was induced in myc-expressing cells cultured in serum-
free media and the consequent apoptosis could be abrogated by exogenous sur-
vival factors, by forced overexpression of Bcl-2 or the related Bcl-XL protein or by
disruption of the FAS death signaling circuit [Hueber et al., 1997]. Collectively, the
data indicate that the apoptotic program of the cell can be triggered by an over-
expressed oncogene. Indeed, elimination of cells bearing activated oncogenes
by apoptosis may represent the primary means by which such mutant cells are
continually eliminated from the tissues.
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1.5 Objectives
Hepatocellular carcinoma (HCC) and obesity are intimately connected diseases
and their incidences are steadily increasing worldwide. Thus, the obesity- asso-
ciated increase in HCC development gains substantial clinical relevance.
Previous work clearly evidenced the promoting role of IL-6 in liver tumori-
genesis [Naugler et al., 2007]. Nevertheless, how IL-6 signaling facilitates HCC
growth in the tumor itself or in the tumor microenvironment or whether both are
affected by IL-6 still remains elusive.
To precisely define the effects of IL-6 signaling pathway in tumors and in cells
contributing to the tumor microenvironment through a loss of function approaches
in mice, the IL-6Rα was genetically deleted in the entire body, hepatocytes, myeloid
cell and T cells of mice, respectively. A DEN induced liver carcinogenesis ap-
proach was applied to these mice to confirm the previously published protec-
tion of IL-6 signaling deficient animals to DEN induced HCC development and
to elucidate the underlying mechanism. Moreover, a group DEN injected mice
were also exposed to HFD feeding since HFD increased tumor number and size
in different HCC tumor model [Park et al., 2010; Wunderlich et al., 2008].
Taken together, these experiments should determine the molecular mechanisms
and the cell type (s) responsible for mediating the recently published protection
to HCC development in IL-6 knock out mice. Thus, this work will clarify whether
the tumor originating from hepatocytes or specific cell types contributing to the
microenvironment such as macrophages and T lymphocytes mediate IL-6’s abil-
ity to promote tumor growth in the HCC mouse model.
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2.1 Materials
2.1.1 Chemicals
Table 2.1: Chemicals
Chemical Supplier
β-mercaptoethanol Applichem, Darmstadt, Germany
e-aminocaproic acid Sigma-Aldrich, Seelze, Germany
0.9% saline (sterile) Delta Select, Pfullingen, Germany
2,2,2-Tribromoethanol (Avertin) Sigma-Aldrich, Seelze, Germany
2-Methyl-2-Butanol Sigma-Aldrich, Seelze, Germany
Acetic acid Merck, Darmstadt, Germany
Acetone KMF Laborchemie, Lohmar, Germany
Acrylamide Roth, Karlsruhe, Germany
Agarose Peqlab, Erlangen, Germany
Agarose (Ultra Pure) Invitrogen, Karlsruhe, Germany
Ammonium Acetate Merck, Darmstadt, Germany
Ammoniumpersulfat (APS) Sigma-Aldrich, Seelze, Germany
Aprotinin Sigma-Aldrich, Seelze, Germany
Bacillol Bode Chemie, Hamburg, Germany
Benzamidine Sigma-Aldrich, Seelze, Germany
Bovine serum albumin (BSA) Sigma-Aldrich, Seelze, Germany
Bromphenol blue Merck, Darmstadt, Germany
Calcium chloride Merck, Darmstadt, Germany
Chloroform Merck, Darmstadt, Germany
Continued on next page
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Table 2.1 – continued from previous page
Chemical Supplier
Desoxy-ribonucleotid-triphosphates
(dNTPs)
Amersham, Freiburg, Germany
Developer G153 AGFA, Mortsel, Belgium
Dimethylsulfoxide (DMSO) Merck, Darmstadt, Germany
di-Natriumhydrogenphosphat Merck, Darmstadt, Germany
Di-thiothreitol Applichem, Darmstadt, Germany
Enhanced chemiluminescence (ECL) Kit Perbio Science, Bonn, Germany
Ethanol, absolute Applichem, Darmstadt, Germany
Ethidium bromide Sigma-Aldrich, Seelze, Germany
Ethylendiamine tetraacetate (EDTA) Applichem, Darmstadt, Germany
Fixer G354 AGFA, Mortsel, Belgium
Forene (isoflurane) Abbot GmbH, Wiesbaden, Germany
Glucose 20% DeltaSelect, Pfullingen, Germany
Glycerol Serva, Heidelberg, Germany
Glycine Applichem, Darmstadt, Germany
HEPES Applichem, Darmstadt, Germany
Hydrochloric acid (37%) KMF Laborchemie, Lohmar, Germany
Hydrogen peroxide Sigma-Aldrich, Seelze, Germany
Insulin Novo Nordisk, Bagsvaerd, Denmark
Isopropanol (2-propanol) Roth, Karlsruhe, Germany
Magnesium chloride Merck, Darmstadt, Germany
Methanol Roth, Karlsruhe, Germany
Nitrogen (liquid) Linde, Pullach, Germany
N-Nitrosodiethylamine Sigma-Aldrich, Seelze, Germany
Paraformaldehyde (PFA) Sigma-Aldrich, Seelze, Germany
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, Seelze, Germany
Phosphate buffered saline (PBS) Gibco BRL, Eggenstein, Germany
Potassium chloride Merck, Darmstadt, Germany
Continued on next page
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Table 2.1 – continued from previous page
Chemical Supplier
Potassium dihydrogenphosphat Merck, Darmstadt, Germany
Potassium hydroxide Merck, Darmstadt, Germany
Sodium acetate Applichem, Darmstadt, Germany
Sodium chloride Applichem, Darmstadt, Germany
Sodium citrate Merck, Darmstadt, Germany
Sodium dodecyl sulfate Applichem, Darmstadt, Germany
Sodium fluoride Merck, Darmstadt, Germany
Sodium heparin (Liquemin) Roche, Grenzach-Wyhlen, Switzerland
Sodium hydrogen phosphate Merck, Darmstadt, Germany
Sodium hydroxide Applichem, Darmstadt, Germany
Sodium orthovanadate Sigma-Aldrich, Seelze, Germany
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Seelze, Germany
Tissue Freezing Medium Jung, Heidelberg, Germany
Tramadolhydrochlorid (Tramal) Grünenthal, Aachen, Germany
Trishydroxymethylaminomethane (Tris) Applichem, Darmstadt, Germany
Triton X-100 Applichem, Darmstadt, Germany
Trizol Applichem, Darmstadt, Germany
Tween 20 Applichem, Darmstadt, Germany
Vectashield Mounting Medium with DAPI Vector, Burlingame, USA
Western Blocking Reagent Roche, Mannheim, Germany
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2.1.2 Buffer and solutions
Table 2.2: Buffer and solutions
Buffer/Solution Composition
Anode buffer 1 0,3 M Tris
20% (v/v) Methanol
Anode buffer 2 25 mM tris
20% (v/v) Methanol
Antibody Solution 5% (v/v) Roche Western Blocking
Reagent in TBS-T
Avertin-injectable solution 20.3 mg/ml Avertin Stocksulution
mixed in 0.9 % NaCl
steril filter and store at 4°C in the dark
Avertin-stocksolution 1.6 mg/ml Avertin
in 2-Methyl-2-Butanol
incubate for 12 h at RT
Cathode buffer 40 mM 6-Aminocapron acid
0.01 % (v/v) SDS
20% (v/v) Methanol
Organ Lyses Buffer 50 mM HEPES
1 % Triton X-100
50 mM NaCl
0.1 M NaF
10 mM EDTA
10 mM Sodium orthovanadat
0.1 % (w/v) SDS
2 mM Benzamidin
10 µl/ml Aprotinin
adjust pH 7.4
2 mM PMSF
Continued on next page
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Table 2.2 – continued from previous page
Buffer/Solution Composition
PBS (1x) 137 mM NaCl
2.7 mM KCl
8.1 mM Na2HPO4
1.5 mM KH2PO4
adjust pH 7.4
SDS-PAGE electrophorese buffer (10x) 0.25 M Tris
2 M Glycin
35 mM SDS
SDS-protein-loading-buffer (4x) 250 mM Tris-HCl, pH 6.8
200 mM DTT
8% (v/v) SDS
0.04% (w/v) Bromphenolblue
40% (v/v) Glycerol
Stripping solution 0.7% β-Mercaptoethanol
2% (v/v) SDS
12.5% 0.5 M Tris, pH 6.8
TAE (50x) 2 M Tris
50 mM EDTA
adjust pH 8 with acetate acid
Tail-Lyses-Buffer 100 mM Tris-HCl, pH 8.5
200 mM NaCl
5 mM EDTA
0.2% (w/v) SDS
TBS (10x) 1.47 M NaCl
0.2 M Tris
adjust pH 7.4
TBS-Tween (1x) 1 x TBS
0.1% Tween20
Continued on next page
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Table 2.2 – continued from previous page
Buffer/Solution Composition
TE-Buffer 10 mM Tris-HCl, pH 7.4
10 mM EDTA, pH 7.8
Western Blocking solution 10% (v/v) Roche Western Blocking
Reagent in TBS-T
2.1.3 Kits
Table 2.3: Kits
Kit Company
Real-time detection PCR
TaqMan universal PDR master mix Applied Biosystems, Darmstadt, Ger-
many
Reverse transcription PCR
Reverse transcription core kit Qiagen, Hilden, Germany
SuperScript III first-strand kit Invitrogen, Karlsruhe, Germany
RNA isolation
RNAeasy extraction kit Quiagen, Hilden, Germany
peqGOLD TriFast Peqlab, Erlangen, Germany
Developing of western blots
Enhanced chemiluminescence kit Amersham Pharmacia Biotech,
Freiburg, Germany
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2.1.4 Enzymes
Table 2.4: Enzymes
Enzymes Supplier
DNase Promega, Mannheim, Germany
Proteinase K Roche Diagnostics, Basel, Swiss
DreamTaq ThermoScientific, Schwerte, Germany
RNase A ThermoScientific, Schwerte, Germany
2.1.5 Standards
Table 2.5: Standards
Standard Company
GeneRulerTM DNA ladder mix ThermoScientific, Schwerte, Germany
PageRulerTM protein ladder ThermoScientific, Schwerte, Germany
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2.2 Animal care
Keeping of mice, used for the experiments, occured in agreement with the animal
protection guidelines of the district president of Cologne. The authorization for
animal procedures was approved by the district government of Cologne and in
accordance with NIH guidelines. Authorization for accomplishment of the ex-
periments: 50.203.2 – K 13, 35/03 Genetic analysis of molecular mechanisms in
the regulation of gluconeogenesis and glucose disposal. The mice were housed
in a constant 12 hour day-night-cycle, the room temperature was constantly 22°C
and they had ad libitum access to food and drinking water. After weaning (P21),
mice were separated by sex and were kept in groups of 2 to 5 animals per cage.
During weaning the mice were marked by eartags. For genotyping by PCR the
tail top was cut. During the experiments the mice were exposed to high fat diet
(HFD; C1057; Altromin) containing 32.7 % carbohydrates, 20 % protein, and 35.5
% fat (55.2 % of calories from fat) or normal chow diet (NCD; Teklad Global Ro-
dent 2918; Harlan) containing 53.5 % carbohydrates, 18.5 % protein, and 5.5 % fat
(12 % of calories from fat).
2.3 Metabolic measurements
2.3.1 Serum extraction
Blood samples were taken from the mice by two different methods. Blood was
either collected from the tail vene or from the submandibular veins by piercing
the cheek with a lancet. For coagulation the blood was stored on ice for 30 min-
utes and afterwards centrifuged for 60 minutes at 13.000 rpm at 4 °C. The blood
serum was collected and frozen at -20 °C until further application.
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2.3.2 Measuring of blood glucose level
For measuring blood glucose level Glucomen® blood glucose meter was used.
Therefore the tail vene was cut and a drop of blood was transfered to Glucomen®-
test strip.
2.3.3 Glucose tolerance test
A glucose tolerance test was used to test metabolic reaction of mice to hypergly-
colemic stimuli. Therefore mice were fasted for 6 hours and afterwards injected
with 2 mg/g body weight glucose i.p.. Blood glucose levels were measures be-
fore, 15, 30, 60 and 120 minutes after injection.
2.4 Treatments
2.4.1 Diethylnitrosamine (DEN)-injection
Liver tumors were induced by DEN to investigate the role of IL-6 in hepato-
carcinogenesis. Mice were injected intra peritoneal (i.p.) with 25 mg/kg DEN
(Sigma) 15 days after birth for long term studies. Tumor development was inves-
tigated for 8 months. For short term studies 8 weeks old mice were injected i.p.
with 100 mg/kg DEN and sacrificed 4, 12, 24 hours or 48 hours after injection.
2.4.2 IL-6 signaling
50 ng recombinant IL-6 was injected either via the Vena carva or via tail vene in
8 weeks old mice to induce IL-6 signaling and mice were sacrificed at different
time points.
2.4.3 NK T cell induction
Eight weeks old mice were injected i.p. with 4 µg Galactosylceramide to specifi-
cally activate NK T cells and sacrificed at different time points.
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2.4.4 Constitutiv active GSK-3 via Adeno-associated-virus (AAV)
8 weeks old mice were injected with 5 x 101 viral particles 5 days before DEN
treatment to test the effect of constitutive active GSK-3β (GSK-3βCA). Adeno-
associated viral vector particle production was carried out by calcium phosphate
transient co-transfection of the vector plasmid p87GSK-3CA or pscAAV/EGFP,
pXR8 AAV serotype 8 helper plasmid (kindly provided by James Wilson, Univer-
sity of Pennsylvania, Philadelphia, USA) and pXX6-80 adenovirus helper plas-
mid (kindly provided by Jude Samulski, University of North Carolina at Chapel
Hill, USA) into human embryonic kidney 293 (HEK293) cells. p87GSK-3βCA
contained the TTR-promoter driven GSK-3CA cassette that was amplified from
mouse liver cDNA using primers 5NcomycGSKCA: ccATGGGCGGCGAGCA-
GAAACTCATCTCTGAAGAGGATCTGTCGGGGCGACCGAGAACCACCgCC
TTTGCGGAGAGCTGCAAGCC and 3NotGsk3: GCGGCCGCTCAGGTGGAGT
TGGAAGCTG and subsequently cloned into p87 using restriction endonucle-
ases NcoI and NotI thereby replacing the luciferase transgene by GSK-3CA. p87
is designed for production of AAV8-inverted terminal repeat (ITR)-flanked self-
complementary AAV vector genomes. HEK293 cells were harvested post trans-
fection and subjected to benzonase treatment after lysis. AAV particles were pu-
rified using a discontinuous iodixanol gradient (15-60%). Recombinant viral par-
ticle titer was determined by qPCR and found to be 2 x 109 per µl for AAV8 TTR
GSK-3βCA and 3,3 x 108 for AAV8 GFP. The control vector encoding for GFP was
produced accordingly.
2.4.5 PI-3K-inhibitor
8 month old mice injected with 25 mg/kg DEN were treated with 1 mg of PI3K
inhibitor GDC-0941 by oral gavage daily for 10 days to inhibit PI3K and were
subsequently sacrificed. GDC-0941 was dissolved as previously described (Sos et
al., 2009).
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2.4.6 Depletion of regulatory T cells
Thirteen days old mice were injected with 1 mg αCD25 antibody to deplete reg-
ulatory T cells before injection with 100 mg/kg DEN injection on day 15 initiates
tumor development.
2.4.7 PP-1 inhibition by Ocadaic acid
Eight weeks old mice were injected i.p. with 0.75µg/kg BW ocadaic acid to specif-
ically inhibit PP-1 activity 1 hour before DEN injection. Mice were sacrificed at
different time points.
2.5 Organ preparation
2.5.1 Organ extraction
After 8 weeks (short-term experiments) and 8 month (long-term experiments), re-
spectively, mice were sacrificed with CO2. Blood was taken from the heart, liver,
muscle, white adipose tissue and brain were extracted and shock frozen in liq-
uid nitrogen. A small part of the liver was embedded in tissue freezing medium
for subsequent tissue slices. The big lobe of the liver of mice from the long-term
experiments was deposite in formalin for further analysis. White adipose tissue
was weighed. The organs were stored at -80 °C until further application.
2.5.2 Tumor quantification in the liver
For the macroscopical quantification tumor numbers in livers of eight months old
mice were determined. Livers were extracted and tumors were counted which
were visible by eye. The big lobe of the liver from eight months old mice (long-
term experiment) was deposited in formalin and sent to Beate Straub, a pathol-
ogist in the Institute of Pathology in the University Hospital in Heidelberg, for
microscopical analyses.
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2.5.3 Liver status
Quantitation of inflammation measured in the big liver lobe of DEN-injected 8
month old mice was performed by the following score:
1 = mild inflammation (mild portal inflammation, 3-5 single cell necrosis, no
grouped necrosis)
2 = moderate inflammation (moderate portal inflammation, 6-9 single cell necro-
sis, 1 grouped necrosis)
3 = severe inflammation (severe portal inflammation, more than 10 single cell
necrosis, more than 1 grouped necrosis)
Quantitation of steatosis measured in the big liver lobe of DEN-injected 8 month
old mice was performed by the following score:
1 = 0 - 10%
2 = 11 - 50 %
3 = above 50 %
Quantitation of fibrosis measured in the big liver lobe of DEN-injected 8-mo
mice was performed by the following score:
1 = increased portal connective tissue
2 = early formation of septa
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2.6 Bio molecular methods - nucleic acids
2.6.1 DNA-isolation from tail cuts
To isolate genomic DNA from tailcuts, tails were incubated with 600 µl tail lysis
buffer containing Proteinase K (1:100) at 55°C over night. On the next day lysed
tails were centrifuged for 10 minutes at 10.000 rpm to collect coat residues. The
supernatant was mixed with 600 µl isopropanol for precipitation of DNA. The
mix was centrifuged at 13.000 rpm for 15 minutes, the supernatant was discarded
and pellet was washed with 200 µl 70 % ethanol. After centrifugation at 13.000
rpm for 10 minutes, the supernatant was again discarded and DNA pellet dried
for 15 minutes. The DNA was resuspended in 50 µl Tris-EDTA buffer containing
RNase A (1:1000).
2.6.2 RNA-isolation with RNAeasy kit
To obtain pure RNA for real-time analysis RNAeasy Mini Kit (Qiagen) was used.
The procedure was performed according to the RNAeasy Mini Kit protocol for
purification of total RNA from animal tissue.
2.6.3 Determination of nucleic acid concentration
For quantitation of DNA or RNA in solution a spectral photometer was used. The
photometer measured optical density at a wavelength of 260 nm. The absorption
of purine and pyrimidine aromatic bases is maximal at this wavelength. The
following formula was used for determination of DNA:
C [ng/µl] = OD260 x D x E
C = concentration of DNA solution OD260 = absorption at 260 nm D = dilution
factor E = extinction coefficient
Around 50 µg/ml double-stranded DNA or 40 µg/ml RNA or single-stranded
DNA corresponds to an OD260 of 1. Optical density of a wavelength at 280 nm
was measured to detect protein contaminations. A ratio between 1.8 – 2.0 (OD260
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/OD280) shows minimal protein contaminations. Measurements were done in
the NanoDrop® instrument.
2.6.4 Polymerase chain reaction (PCR) for genotyping of mice
Table 2.6: Primer
Primer notation Sequence
5’Cre ACG AGT GAT GAG GTT CGC A
3’Cre ATG TTT AGC TGG CCC AAA TGT
5’IL6Ex3 CCA GAG GAG CCC AAG CTC TC
3’IL6a TAG GGC CCA GTT CCT TTA T
5GK12 CCGCGGGCGATCGCCTAGG
5’gp130 GGT GGC TGA TTC ACC TGC A
3’gp130 TAC GCT GGG CAG CGT CCT
gp130 delta AAC ACA CTC ATG CTG AAA CC
Table 2.7: PCR mix
Reagent Amount
H2O 20.1 µl
Buffer 2.5 µl
dNTPs 0.2 µl
Primer 0.25 µl per primer
DreamTaq 0.2 µl
DNA 1.5 µl
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Table 2.8: PCR programms
PCR Programm
Cre 95◦C 30 sec
95◦C 30 sec
54◦C 30 sec
72◦C 1 min
72◦C 5 min
4◦C endless
IL-6Rα 94◦C 3 min
94◦C 45 sec
54◦C 45 sec
72◦C 1.30 min
72◦C 10 min
4◦C endless
gp130 94◦C 4 min
94◦C 30 sec
54◦C 30 sec
72◦C 45 min
72◦C 10 min
4◦C endless
2.6.5 Agarose gel electrophoresis
Gel electrophoresis was used to separate DNA with different size.
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2.6.6 Reverse transcription (RT)
A RT-PCR was performed to produce cDNA for real-time analysis. Using the
High Capacity cDNA Reverse Transcription Kit from Applied Biosystems, RT-
PCR was performed according to manufacturer’s instructions.
Table 2.9: RT programm
Temperature Time
25◦C 10 min
37◦C 2 h
85◦C 5 min
4◦C endless
Table 2.10: RT mix
Reagent Amount
RNase free H2O 4.2 µl
10x Buffer 2 µl
dNTPs 0.8 µl
random Oligos 2 µl
reverse transkriptase 0.25 µl
RNA 1-2 µg in 10 µl
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2.6.7 Quantitative real-time PCR (qRT-PCR)
Quantitative qRT-PCR was performed to measure expression levels, using Taq-
Man probes from Applied biosystem. The qRT-PCR was performed as followed.
Table 2.11: Oligonucleotides for qRT-PCR (applied Biosystems, Darmstadt, Germany)
Probe Order number
Bak Mm00432042m1
Bax Mm00432045m1
Bbc3 Mm00519268m1
Bcl-2 Mm00477631m1
Bclxl Mm00437783m1
Clcf-1 Mm0136492m1
Cntf Mm00446373m1
Cntfr Mm00516693m1
Ctf-1 Mm00432772m1
Cul1 Mm00516318m1
Ebi-3 Mm00469294m1
Fbxw7 Mm00504452m1
gp130 Mm00438665m1
Gusb Mm00446953m1
Huwe1 Mm00615533m1
IL-6 Mm00446190m1
IL-11 Mm00434162m1
IL-33 Mm00505403m1
IL-6ra Mm00439649m1
IL-11ra Mm00494938m1
IL-20ra Mm00555504m1
Lif Mm00434762m1
Lifr Mm00442942m1
Mcl-1 Mm01257352g1
Continued on next page
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Table 2.11 – continued from previous page
Probe Order number
Osm Mm01193966m1
Osmr Mm01307326m1
Pmaip1 Mm00451763m1
Pp1ca Mm00453291g1
Puma Mm00437783m1
Table 2.12: Realtime mix
Reagent Amount
DEPC- H2O 3.4 µl
MasterMiix (TaqMan) 6 µl
probe 0.6 µl
cDNA 2 µl
2.6.8 Chromatin Immunoprecipitation
HepG2 cells were grown on 15cm dishes to 80-90% confluency in EF Medium.
Cells were stimulated with 200 ng/ml human IL-6 (#200-006, PeproTech) for 45
minutes and subsequently crosslinked with 1% PFA for 10 minutes at room tem-
perature. The reaction was quenched with addition of 1.7 ml 1.25 M Glycine
for 5 minutes and cells were washed twice with PBS. Cells were scraped off the
plates in 2 ml PBS, supplemented with protease inhibitor (Roche cOmplete pro-
tease inhibitor cocktail), and collected in 15 ml falcon tubes (700 xg, 5 minutes,
4°C). The cell pellet was resuspended in 1 ml cell lysis buffer (5 mM HEPES, 140
mM NaCl, 1 mM EDTA, 10% Glycerol, 0.25% Triton X-100, 1 mM PMSF, Roche
cOmplete protease inhibitor cocktail) and rotated for 15 minutes at 4°C. Cells
were collected (700 xg, 5 minutes, 4°C), resuspended in 1 ml MNase Buffer (0.32
M Sucrose, 50 mM Tris-HCL pH7.5, 4 mM MgCl2, 1 mM CaCl2, 0.1 mM PSMF,
Roche cOmplete protease inhibitor cocktail, 300u MNase [Thermo Scientific]) and
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incubated at 4°C for 60 minutes. Cells were collected (700 xg, 5 minutes, 4°C), re-
suspended in 1 ml nuclear lysis buffer (50 mM Tris-HCL pH8.0, 10 mM EDTA,
1% SDS, 1 mM PMSF, Roche cOmplete protease inhibitor cocktail) and again ro-
tated for 15 minutes at 4°C. The cell suspension was sonicated with 20 pulses a
30 seconds (Branson Sonifier 250, output control 4, duty cycle 50%, 90 seconds
cooldown between pulses). 100 µl cell suspension, containing 1x106 cells, were
used per immunoprecipitation. Subsequent sample handling was done with the
EZ-ChIP kit (#17- 371, Millipore) according to the manufacturer’s instructions.
Immunoprecipitation was performed with an antibody against RNA-Polymerase
II, mouse IgG (both included with the kit) and an antibody against p-Stat3 Y705
(#9145, Cell-Signaling). Precipitation of the promoter regions was analyzed by
PCR, utilizing the primers
5hMULEChIP (GAGGGAAGGAGTCTGGATAAT) and 3hMULEChIP (CCGATC-
TAGGTGTCTAGAGC) or 5hMULEUSChIP (GCATTGTATGATTGTACTACAGTT-
TAT) and 3hMULEUSChIP (CCAGCGGTTACTCTTCTAAGAA) for MULE, re-
sulting in 296 bp and 180 bp fragments respectively; 5hPP1CAChIP (AGTGCGCTG
GGAATTCAGCC) and 3hPP1CAChIP (GAGGCGCCCAGCCCTGT) for PP1CA,
resulting in a 307 bp fragment.
2.7 Bio molecular methods - proteins
2.7.1 Extraction of proteins from mouse organs
To extract proteins from mouse organs the organs were covered with 1 ml organ
lysis buffer and homogenized with an Ultraturrax. Afterwards the homogenate
was centrifuged for one hour at 13.000 rpm at 4 °C. After centrifugation the clear
medial of the three phases was collected in a new tube and the protein content
was measured by the Warburg-method. The absorption of the protein solution
was measured at 280 nm.
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2.7.2 Mitochondrial isolation
Isolation of mitochrondria from mouse liver was done as previously described
(Frezza et al., 2007). Mitochondria were washed twice in MSB (400mM manitol,
10 mM KH2PO4, 50 mM Tris-HCl, 0.5% BSA, pH 7.2) and protein concentrations
were determined (BCA Protein Assay, Pierce).
2.7.3 Bax treatment of isolated mitochondria
100 µg mitochondria, supported with 1 mM ATP, 5 µM rotenone and 4 mM
MgCl2, were treated with increasing amounts of recombinant Bax protein (0.25µg-
1µg; SignalChem) for 30’ at 30°C. After centrifugation (20.000g), the supernatant
was further analyzed by western-blot for release of cytochrome c.
2.7.4 SDS-polyacrylamid-gelelectrophorese (SDS-PAGE)
For electrophoretic separation by means of their molecular size protein samples
were diluted with organ lyses buffer and 4x SDS-loading dye to a concentration of
10 µg/µl. The samples were heated to 98 °C for 5 minutes to denaturate proteins
for SDS binding. In the experiments 10 % and 15 % resolving gels where used.
2.7.5 Western blot analysis
For determination of protein levels, proteins, which were separated by SDS-PAGE,
were transferred onto a Polyvinylidendifluorid (PVDF)-membrane. A Semi-Dry-
Blot and a Wet-Blot were used bevor blocking for one hour in 1 % Western Block-
ing reagent in TBS-T. First antibody were diluted in 0,5 % Western Blocking reagent
(antibody dilution in 2.13) and incubated at 4° C over night. The second antibody
were diluted in 0.5 % Western Blocking reagent (antibody dilution in 2.13) and
incubated for one hour at room temperature. For detection 10 ml ECL was used
for one minute. For reuse membrane was stripped 30 minutes in a 56°C water
bath with stripping solution.
2 Materials and Methods 39
Table 2.13: Antibodies
Antibodies Type Dilution Supplier
α-panAKT rabbit,
monoclonal
1:1000 Cell Signaling, Danvers, USA
α-Bax rabbit,
monoclonal
1:500 Santacruz, Heidelberg, Germany
α-Bcl-2 rabbit,
monoclonal
1:500 Santacruz, Heidelberg, Germany
α-BclXL rabbit,
monoclonal
1:500 Santacruz, Heidelberg, Germany
α-Calnexin rabbit,
monoclonal
1:1000 Millipoore, Germany
α-cleaved
Caspase 3
rabbit,
monoclonal
1:500 Cell Signaling, Danvers, USA
α-Complex II rabbit,
monoclonal
1:1000 Santacruz, Heidelberg, Germany
α-GSK-3β rabbit,
monoclonal
1:1000 Cell Signaling, Danvers, USA
α-Mcl-1 rabbit,
monoclonal
1:2000 Rockland Inc., Gilbertsville, PA 19525
α-pAKT rabbit,
monoclonal
1:1000 Cell Signaling, Danvers, USA
α-pERK 1/2 rabbit,
monoclonal
1:1000 Cell Signaling, Danvers, USA
α-pGSK-3β rabbit,
monoclonal
1:1000 Cell Signaling, Danvers, USA
α-pJNK rabbit,
monoclonal
1:1000 Cell Signaling, Danvers, USA
Continued on next page
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Table 2.13 – continued from previous page
Antibodies Type Dilution Supplier
α-Puma rabbit,
monoclonal
1:1000 Cell Signaling, Danvers, USA
α-pStat-3 rabbit,
monoclonal
1:1000 Cell Signaling, Danvers, USA
α-rabbit,
conjugated
with peroxi-
dase
rabbit,
monoclonal
1:1000 Sigma, Deisenhofen, Germany
2.7.6 Quantitation of western blots
Quantitation of Western blots was done by Quantity One by BioRad.
2.8 Bio molecular methods - serum
2.8.1 Serum analysis
For evaluation of liver injury, levels of glutamate-pyruvate-transaminase and
aspartate-aminotransferase in the serum were measured. Level of triglycerides
and cholesterol were also measured. Serum was diluted 1:10 in 0.9 % NaCl and
measured in the central lab of the university hospital in cologne.
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2.8.2 Insulin, Leptin, IL-6 and TNFα enzyme linked immuno sorbent assay
(ELISA)
Serum insulin (mouse Insulin ELISA, Crystal Chem inc.), serum leptin (mouse
leptin ELISA, Crystal Chem inc.), serum TNFα (Quantikine Immunoassay ELISA
TNFα, R&D Systems), serum sgp130 (Glucoprotein 130 ELISA kit, antikörper-
online), serum IL-6 sR (Quantikine Immunoassay ELISA IL-6, R&D Systems) and
serum IL-6 (Quantikine Immunoassay ELISA IL-6, R&D Systems) were deter-
mined by ELISA according to manufacturer’s instructions.
2.8.3 AKT, Caspase-3, GSK-3β and PI3K activity assay
AKT activity (AKT kinase assay, Cell Signaling), Caspase-3 activity, (PathScan
Cleaved Caspase 3 ELISA kit, Cell Signaling), GSK-3β activity (GSK-3β activity
assay, sigma-aldrich) and PI3K activity (PI-3 kinase activity assay, echolon) in
liver lysates were determined according to manufacturer’s instructions.
2.9 Immunohistochemical and immunofluorescence stainings
2.9.1 HE staining
For histological analysis of tumors formalin-fixed liver specimen were embedded
in paraffin, 2 µm sections were cut and stained with hematoxylin/eosin, distase-
PAS silver stain.
2.9.2 Mcl-1 staining
For histological analysis of tumors formalin-fixed liver specimen were embedded
in paraffin, 2 µm sections were cut and stained Mcl-1 (abcam #32087) or HUWE1
(lifespan biosciences LS-B1359/20559).
2.9.3 Oil Red O staining
Steatosis was detected by Oil-Red-O Staining.
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2.9.4 TUNEL staining
Tissue sections were used for DeadEnd Fluorometric TUNEL system (Promega)
according to manufacturer’s instructions to detect apoptotic cells. TUNEL- posi-
tive cells were quantified using image tool software (Imaris 7.0).
2.9.5 Ki67 staining
To detect proliferating cells, tissue sections were stained with Ki67 antibody (#ab
15580, Abcam) and donkey α-rabbit red (#711-025-152, Jackson). Ki67-positive
cells were quantified using image tool software (Imaris 7.0).
2.10 Cell culture
2.10.1 Dual Luciferase Reporter Assay
For the pTE-MULE-Luc reporter construct generation, 1000 bp promoter region
of the mouse MULE locus were inserted downstream of the luciferase open read-
ing frame in the pTE-Luc plasmid instead of the CAG promoter (Jordan et al.,
2011, Nat Cell Biol). The MULE promoter was amplified by PCR with the primers
5MluMule (ACGCGTTATAGACTTTAGGCAGTCTG) and 3NcoMule (CCATG-
GTTTTCAGTTTTCTGATTTAAG). Insertion into pTE-Luc was performed with
NcoI-MluI double restriction. HepG2 were plated on 6-well plates and trans-
fected with 1000 ng DNA (100 ng pRL-Null and 900 ng pTE-MULE-Luc) using
the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manu-
facturer’s instructions. 24 hours after transfection, cells were pre-incubated with
20 µM STATTIC Stat3 inhibitor for 1 hr (#573099, Calbiochem, DMSO vehicle,
manufacturer’s instruction were followed) and subsequently stimulated with 250
ng/ml human IL-6 (#200-006, PeproTech) over night respectively. Dual luciferase
reporter assays were performed 48 hours after transfection using a luciferase As-
say System (Promega) according to the manufacturer’s instructions.
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2.10.2 Primary murine hepatocyte and human hepatoma culture
Anesthesized mice were perfused 5 min with EBSS solution (Gibco, 4155-048)
containing 0.5 mM EGTA via vena cava. Subsequently, mice were perfused with
50 ml EBSS (Gibco, 24010-043) containing 10 mM Hepes, 15 mg Collagenase
Type II (Worthington) and 2 mg Trypsin inhibitor (Sigma). After perfusion,the
liver was transferred in 10 ml ice cold EBSS (Gibco, 24010-043) containing 10
mM Hepes. The gall bladder was removed and hepatocytes were released from
the cell association. The cell suspension was pressed through a sieve with 20
µm mesh and centrifuged for 5 min. at 500 g at 4°C. The supernatant was re-
moved and the pellet was washed twice in William’s E medium (PPA) containing
6 ml sodium pyruvate, 6 ml non essential amino acids, 30 ml FCS, 6 ml Peni-
cilin/Streptamycin, 6 ml Glucose, 11,5 ml Hepes and 6 ml Glutamate. Subse-
quently, the pellet was dissolved in 10 ml medium. The viability should be >90
%, as determined by trypan blue dye exclusion. 3x106 hepatocytes isolated from
control and IL-6Rα-deficient animals were incubated with medium containing
DEN at different concentrations for 48 h. Subsequently, mitochondria and cy-
tosolic fractions were separated and used for Western blot analysis. Hep3B cells
were cultivated in hepatocyte medium and stimulated with 50 ng human IL-6
(#200-006, PeproTech) for the indicated time. Neutralization of hIL-6R using anti-
IL-6Rα (R&D mab227) and control rat IgG (BD 554682) was performed prior to
IL-6 treatment.
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3.1 Obesity increases basal hepatic Stat-3 activation and
impairs acute IL-6 responsiveness
To determine the molecular mechanisms mediating the recently published pro-
tection to HCC development in IL-6 deficient mice, the IL-6Rα was genetically
deleted in the entire body and a DEN induced liver carcinogenesis approach was
applied. Furthermore, DEN injected mice were exposed to HFD feeding to deter-
mine the effect of obesity to HCC development.
IL-6 initiates downstream signaling by binding to the IL-6 receptor (IL-6R),
whose activation results in multiple downstream signaling events in the liver
such as activation of the JAK/Stat-3 and MAPK/ERK pathways [Heinrich et al.,
1998].
To determine the time course of IL-6 activated downstream signaling 8 weeks
old control mice were injected with 50 ng IL-6 / g BW intraveneously (i.v.) and
phosphorylation of several downstream targets were analysed by western blot
after 30, 60, 120 and 240 minutes. Phosphorylation of Stat-3 appeared already 30
min post IL-6 injection and progressively declined thereafter whereas activation
of ERK-1/2 was detected after 30 min and progressively increasing up to 120 min
(Fig. 3.1A). However, IL-6 injection did not activate hepatic JNK phosphoryla-
tion in control mice (Fig. 3.1A). Next, dose response to IL-6 in lean control mice
was measured by western blotting. IL-6-induced Stat-3 activation in liver was
detected upon injection of 3 ng IL-6/g body weight (BW) intraperitoneally (i.p.),
but increased dose-dependently when 30 and 300 ng IL-6/g BW were applied
(Fig. 3.1B). To investigate the effect of obesity to IL-6 signaling lean and obese
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Figure 3.1: IL-6 responisveness in control mice on NCD and HFD
(A) Western blot analysis using pStat-3, pERK1/2, pJNK, and AKT antibodies
on liver tissue from 8 wk C57BL/6 mice after i.v. injection of 50 ng IL-6 / g
BW. (B) Western blot analysis using pStat-3 and Calnexin antibodies on liver
tissue from control mice 1 hr post i.p. injection of indicated amounts of IL-6 /
g BW. (C) Western blot analysis using pStat-3 and Calnexin antibodies on liver
tissue of control mice exposed to NCD or HFD for 23 wk before and 1 hr after
i.p. injection of 50 ng IL-6 /g BW. (D) Body weight of from C at 24 wk (n=7).
Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001
versus control. Data in B/C/D produced in collaboration with Jan Mauer.
mice were injected with 50 ng IL-6/g BW i.p. (Fig. 3.1C/D). While injection of
50 ng IL-6/g BW induced a strong hepatic activation of Stat-3 in lean mice, this
response was massively decreased in obese control mice (Fig. 3.1C/D). Further-
more, livers from obese mice displayed increased Stat-3 activation in the basal
state compared to lean mice (Fig. 3.1C/D).
Collectively, these experiments demonstrate that obesity increases basal Stat-3
activation and impairs the responsiveness to acute IL-6 stimulation.
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3.2 Generation of IL-6Rα knock out mice
To adress the role of IL-6Rα signaling in the development of hepatocellular car-
cinoma (HCC), a conditional IL-6Rα mouse strain, in which exon 2 and 3 of the
IL-6Rα gene are flanked by loxP sites (IL-6Rα f l/ f l) was used [Wunderlich et al.,
2010]. These mice were crossed to mice expressing the Cre recombinase under the
control of the human cytomegalovirus minimal promoter [Schwenk et al., 1995]
and further intercrossed with siblings leading to mice lacking the IL-6Rα in the
whole body (IL-6Rα∆/∆). IL-6Rα f l/ f l mice served as controls throughout experi-
ments.
Determination of efficiency and specificity was previously shown in "The role
of Interleukin 6 in the development of hepatocellular carcinoma" [Gruber, 2009].
As this work is mainly focussed on the liver, determination of efficiency in the
liver was tested again (Fig. 3.2A). qPCR of liver cDNA of control and IL-6Rα∆/∆
mice revealed the absence of IL-6Rα expression in IL-6Rα∆/∆ mice (Fig. 3.2A). Ac-
cordingly, IL-6 was unable to induce hepatic Stat-3 phosphorylation in IL-6Rα∆/∆
mice, whereas CNTF potently induced Stat-3 activation in these mice (Fig. 3.2B).
Furthermore, Lipopolysaccharide (LPS) was observed to potently induce Stat-
3 and JNK phosphorylation in control mice but failed to activate Stat-3 in IL-
6Rα∆/∆ mice (Fig. 3.2B). Thus, the experiments revealed successful inactivation
of IL-6 signaling in IL-6Rα∆/∆ mice while the responsiveness to alternative IL-
6Rα-independent gp130 cytokines such as CNTF remained unaltered.
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Figure 3.2: Inactivation of IL-6 signaling in IL-6Rα∆/∆
(A) qPCR of IL-6Rα in livers of control and IL-6Rα∆/∆ mice (n=6). (B) Western
blot analysis using pStat-3, pERK1/2, pJNK and Calnexin antibodies on liver
tissue from 8 wk old control and IL-6Rα∆/∆ mice after i.p. injection of 100 ng
IL-6, CNTF and LPS. Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p
≤ 0.01; ***, p ≤ 0.001 versus control. Data in B produced in collaboration with
Justus Ackermann
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3.3 HFD causes obesity in control and IL-6Rα∆/∆ mice in the
DEN-induced HCC model
HCC represents a classical inflammation-induced cancer entity whose develop-
ment is significantly enhanced under obese conditions. To investigate whether
IL-6Rα deficiency affects HCC development under lean and obese conditions,
male IL-6Rα f l/ f l and IL-6Rα∆/∆ mice were injected with 25 mg/kg BW DEN i.p.
at 15 days of age and separated after weaning in cohorts fed either a NCD or HFD
for 8 month. To examine whether IL-6Rα deficiency has an impact on metabolic
or inflammatory state different parameters were measured.
As expected, upon HFD feeding body weight was significantly increased both
in IL-6Rα∆/∆ and control mice compared to mice fed a NCD, whereas no differ-
ences could be detected between genotypes both upon NCD and HFD feeding
(Fig. 3.3A).
Previously, it could be shown that HFD feeding impairs glucose metabolism
[Xu et al., 2003]. Hence, an i.p. Glucose tolerance test was performed, demon-
strating an unaltered glucose clearance between IL-6Rα∆/∆ and control mice un-
der NCD conditions (Fig. 3.3B). Upon HFD feeding both IL-6Rα∆/∆ and control
mice revealed an impaired glucose tolerance, which was further impaired in IL-
6Rα∆/∆ under HFD conditions (Fig. 3.3B).
Recent studies could demonstrate that serum Insulin and Leptin levels increase
upon HFD feeding [Benoit et al., 2004]. Therefore concentrations of circulating
Insulin and Leptin were measured by ELISA. Insulin levels were significantly in-
creased upon HFD feeding both in IL-6Rα∆/∆ and control mice, but no differences
could be detected between the genotypes neither on NCD nor on HFD conditions
(Fig. 3.3C). Upon NCD no difference in Leptin levels could be detected between
the genotypes, whereas HFD feeding led to a significant increase of serum Leptin
levels both in IL-6Rα∆/∆ and control mice (Fig. 3.3D). While the Leptin level in
control mice was doubled under HFD conditions compared to NCD conditions,
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IL-6Rα∆/∆ mice revealed a 4-fold increase in serum Leptin level upon HFD com-
pared to NCD feeding (Fig. 3.3D), suggesting a greater impairment in Leptin
signaling.
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Figure 3.3: Metabolic parameters of control and IL-6Rα∆/∆ mice
(A) Weight determination of 8 month (mo) control and IL-6Rα∆/∆ mice (n=15)
injected with 25 mg/kg DEN at 15 days of age and exposed to NCD or HFD
after weaning.(B) Glucose tolerance test of 8 mo control and IL-6Rα∆/∆ mice
(n=6). Examination of (C) serum Insulin concentrations and (D) serum Leptin
concentrations by ELISA from DEN-injected 8 mo control and IL-6Rα∆/∆ mice
(n=8). Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤
0.001 versus control.
To determine the inflammatory status of IL-6Rα∆/∆ and control mice after 8
month of tumor development, inflammatory cytokine such as TNFα and IL-6
were measured by ELISA in the sera of these mice. As expected, TNFα and IL-
6 measurements revealed a significant increase in sera of control and IL-6Rα∆/∆
mice under obese conditions (Fig. 3.4A/B). These data demonstrate that IL-6Rα
deficiency did not affect HFD-induced obesity or obesity-induced insulin resis-
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tance and inflammation.
However, alternative modulation of IL-6 type cytokine signaling by trans- sig-
naling of soluble receptors such as sIL-6Rα and sgp130 might also contribute to
obesity-induced inflammation. Therefore, sIL-6Rα and sgp130 levels in the serum
were measured. While in IL-6Rα-deficient mice the sIL-6Rα was consistently at
the lowest detection level but unchanged between control mice on both diets (Fig.
3.4C), sgp130 was reduced in obese IL-6Rα∆/∆ mice compared to lean but com-
parable to control animals upon HFD feeding (Fig. 3.4D).
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Figure 3.4: Inflammatory signaling in control and IL-6Rα∆/∆ mice
(A) Examination of serum TNFα concentrations, (B) serum IL-6 concentra-
tions, (C) serum sIL-6R concentrations and (D) serum sgp130 concentrations
by ELISA from DEN-injected 8 mo control and IL-6Rα∆/∆ mice (n=8). Dis-
played values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001
versus control.
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To determine the extent of circulating lipids in the blood, cholesterol and triglyc-
eride level in the serum were measured by ELISA. Cholesterol measurement re-
vealed similar levels in control and IL-6Rα∆/∆ mice fed either a NCD or HFD
before DEN treatment (Fig. 3.5A). After DEN treatment Cholesterol levels sig-
nificantly increased upon NCD feeding but remained similar between genotypes
(Fig. 3.5A). Upon HFD feeding no alteration could be detected in both genotypes
compared to untreated mice (Fig. 3.5A). Triglyceride level were completely un-
altered between treated and non-treated mice, diets and genotypes (Fig. 3.5B).
To determine lipid accumulation in the liver Oil red O staining of liver sections
of the four different groups of mice were performed. These stainings revealed
increased hepatic fat storage in mice exposed to HFD feeding in both control and
IL-6Rα∆/∆ animals, although lipid accumulation was comparable between the
genotypes (Fig. 3.5C).
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Figure 3.5: Extent of lipid burden in control and IL-6Rα∆/∆ mice.
(A) Examination of serum Cholesterol level and (B) serum Triglyceride level of
untreated (-) or DEN-injected (+) 8 mo control and IL-6Rα∆/∆ mice (n=10). (C)
Oil Red O stainings of liver sections obtained from DEN-injected 8 mo control
and IL-6Rα∆/∆ mice. Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p
≤ 0.01; ***, p ≤ 0.001 versus control.
Taken together, these experiments demonstrate that HFD exposure causes sim-
ilar levels of obesity in both control and IL-6Rα∆/∆ mice upon DEN induction.
3 Results 53
3.4 IL-6Rα deficiency protects against DEN-induced liver
carcinogenesis but obesity abrogates this effect and
promotes HCC development
In the next step tumor development in 8 mo-old DEN-treated control and IL-
6Rα∆/∆ mice, that had been exposed to either NCD or HFD feeding, was inves-
tigated by visual inspection. Male control NCD-fed mice developed approxi-
mately 30 macroscopically visible liver tumors (Fig. 3.6A/B). 66% of the tumors
were smaller than 2 mm (Fig. 3.4C) whereas 33% reached a size of more than 2
mm (Fig. 3.6D). Similar to IL-6-deficient mice [Naugler et al., 2007], IL-6Rα defi-
ciency potently protected mice from developing DEN-induced HCC upon NCD
feeding (Fig. 3.6A/B). In line with previous studies, obesity increased tumor bur-
den to approximately 50 tumors in control mice (Fig. 3.6A/B) [Park et al., 2010].
However, when IL-6Rα∆/∆ mice were fed a HFD, the protective effect of IL-6Rα
deficiency on HCC development was abrogated as DEN treatment induced sig-
nificantly higher tumor numbers in these mice comparable to control mice upon
HFD feeding (Fig. 3.6A/B).
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Figure 3.6: Turmor burden macroscopic in control and IL-6Rα∆/∆ mice
(A) Livers of 8 mo control and IL-6Rα∆/∆ mice injected with 25 mg/kg BW
DEN at 15 days of age. (B) Quantitation of macroscopic tumor multiplicity
determined by visual inspection in DEN-injected 8 mo control and IL-6Rα∆/∆
mice (n=15). (C) Enumeration of tumor number for < 2 mm and (D) > 2 mm as
determined by visual inspection of DEN-injected 8 mo control and IL-6Rα∆/∆
mice (n=15). Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01;
***, p ≤ 0.001 versus control.
Recent sudies observed that HFD feeding induce hepatic steatosis that can
eventually lead to the development of liver damage and steatohepatitis that in
turn might result in HCC development [Fujii et al., 2013; Nault & Zucman-Rossi,
2010]. As an indirect indicator of liver damage, the activity of the liver aspartate
transaminase (AST) and alanin transaminase (ALT) were measured in the serum
of IL-6Rα∆/∆ and control mice fed either a NCD and or HFD before and after
DEN treatment. AST and ALT levels were not significantly different in the serum
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of control and IL-6Rα∆/∆ mice fed either a NCD or HFD before DEN treatment
(Fig. 3.7A/B). After DEN treatment serum AST levels significantly increased to
the same extent both in control and IL-6Rα∆/∆ mice fed on either a NCD or HFD,
whereas no significant difference could be detected between NCD and HFD fed
mice (Fig.3.7A/B). Serum ALT levels of control and IL-6Rα∆/∆ mice revealed no
increase after DEN treatment neither on NCD nor on HFD feeding (Fig. 3.7A/B).
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Figure 3.7: Liver damage of control and IL-6Rα∆/∆ mice
(A) Determination of serum AST and (B) ALT activity of untreated (-) or DEN-
injected (+) 8 mo control and IL-6Rα∆/∆ mice (n=6). Displayed values are
means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control.
Histological investigation of HE-stained liver sections confirmed that NCD-fed
IL-6Rα∆/∆ mice had significantly decreased number of HCC foci when compared
to NCD-fed control mice (Fig. 3.8A/B). Although, this difference was not as large
as observed upon macroscopic inspection (Fig.3.8A/B). Strikingly, HFD feeding
restored the carcinogenic capability of DEN in IL-6Rα∆/∆ animals as the num-
ber of HCC foci increased to the same extent in control mice and IL-6Rα∆/∆ mice
upon HFD feeding (Fig. 3.8A/B). Furthermore, tumor size was significantly de-
creased in IL-6Rα∆/∆ mice upon NCD feeding compared to control, whereas this
effect was blunted upon HFD feeding demonstrated by similar increase in tumor
size in both IL-6Rα∆/∆ and control mice upon HFD feeding (Fig. 3.8C).
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Figure 3.8: Turmor burden microscopic in control and IL-6Rα∆/∆ mice
(A) HE-stained sections of livers from DEN-injected 8 mo control and IL-
6Rα∆/∆ mice. Asterisks indicate tumor foci; arrows indicate tumorous blood
vessel infiltrates. (B) Quantitation of tumor number per 2 lobules counted on
liver sections from 8 mo control and IL-6Rα∆/∆ mice (n=15). (C) Quantitation
of tumor size measured in the big liver lobe of DEN-injected 8 mo control and
IL-6Rα∆/∆ mice (n=15). Displayed values are means ± S.E.M.; *, p ≤ 0.05; **,
p ≤ 0.01; ***, p ≤ 0.001 versus control. Data produced in collaboration with
Beate Straub.
Moreover, the extent of inflammation as assessed by quantitation of infiltrating
immune cells was significantly reduced in livers of IL-6Rα∆/∆ mice compared to
control mice exposed to a NCD feeding (Fig. 3.9A). In contrast, HFD feeding
significantly increased liver inflammation in both control and IL-6Rα∆/∆ animals
(Fig. 3.9A). Previous studies demonstrated that HFD feeding induce hepatocyte
steatosis that can result in HCC development [Fujii et al., 2013; Nault & Zucman-
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Rossi, 2010]. Livers of IL-6Rα∆/∆ mice fed a NCD revealed a significantly re-
duced extent of steatosis compared to control mice (Fig. 3.9B). Upon HFD feed-
ing the extent of steatosis significantly increased both in control and IL-6Rα∆/∆
mice (Fig. 3.9B). Additionally necrotic hepatocytes per two lobules were counted
which revealed no significant alterations between the genotypes but a significant
increase of necrotic cells in both control and IL-6Rα∆/∆ mice upon HFD feed-
ing (Fig. 3.9C). Fibrosis is often connected with the development of liver can-
cer, therefore the extent of fibrosis was determined by score [Luedde & Schwabe,
2011]. Similar to the analysis of necrotic cells no significant alteration could be
detected between the genotypes but an significant higher extent of fibrosis upon
HFD feeding in both control and IL-6Rα∆/∆ mice (Fig. 3.9D).
Taken together, these data demonstrate that obesity promotes HCC develop-
ment and progression and renders tumor development independent of IL-6Rα
signaling, thus abrogating the protective function of IL-6Rα deficiency under
NCD conditions.
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Figure 3.9: Liver status of control and IL-6Rα∆/∆ mice
(A) Quantitation of inflammation measured in the big liver lobe of DEN-
injected 8 mo control and IL-6Rα∆/∆. 1 = mild inflammation (mild portal
inflammation, 3-5 single cell necrosis, no grouped necrosis); 2 = moderate in-
flammation (moderate portal inflammation, 6-9 single cell necrosis, 1 grouped
necrosis); 3 = severe inflammation (severe portal inflammation, more than 10
single cell necrosis, more than 1 grouped necrosis) (n=15). (B) Quantitation
of steatosis measured in the big liver lobe of DEN-injected 8 mo control and
IL-6Rα∆/∆. 1 = 0 - 10%; 2 = 11 - 50 %; 3 = above 50 % (C) Quantitation of
necrotic cells measured in the big liver lobe of DEN-injected 8 mo control and
IL-6Rα∆/∆. (D) Quantitation of fibrosis measured in the big liver lobe of DEN-
injected 8 mo control and IL-6Rα∆/∆. 1 = increased portal connective tissue; 2
= early formation of septa (n = 15) Displayed values are means± S.E.M.; *, p≤
0.05; **, p≤ 0.01; ***, p≤ 0.001 versus control. Data produced in collaboration
with Beate Straub.
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3.5 Obesity and IL-6 increase HCC development through the
inhibition of mitochondrial apoptosis
IL-6 is a potent survival signal in hepatocytes and deletion of its receptor may
thus affect hepatocyte death signaling and survival. Therefore, apoptosis in the
livers of the different cohorts of mice was examined by determining the presence
of active Caspase 3 by activity assay and western blot analysis.
Increased Caspase 3 activation was detected in liver lysates derived from NCD
fed IL-6Rα∆/∆ mice upon DEN treatment compared to control mice upon NCD
feeding (Fig. 3.10A). Upon HFD feeding Caspase 3 activation was significantly
decreased in IL-6Rα deficient mice compared to NCD-fed IL-6Rα∆/∆ mice (Fig.
3.10A). In comparision to control mice upon HFD feeding, IL-6Rα∆/∆ mice exhib-
ited the same level of Caspase 3 activation upon HFD feeding (Fig. 3.10A). In line
with this observation, Caspase 3 cleavage and thereby activation increased upon
a single DEN injection in livers of IL-6Rα∆/∆ mice compared to control mice (Fig.
3.10B). These data were further substantiated by the finding that AST and ALT
activity was elevated in sera of IL-6Rα∆/∆ mice upon acute DEN injection which
is another strong indicator of liver damage (Fig. 3.10C/D).
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Figure 3.10: Caspase 3 activity in the liver of control and IL-6Rα∆/∆ mice
(A) Determination of Caspase 3 activity using an ELISA based assay on liver
lysates from DEN-injected 8 mo control and IL-6Rα∆/∆ mice (n=5). (B) West-
ern blot analysis using cleaved Caspase 3 and AKT antibodies on liver tissue
from 8 wk control and IL-6Rα∆/∆ mice fed on a NCD sacrificed at the in-
dicated time points after a 100 mg/kg DEN injection. (C) Determination of
serum AST and (D) ALT activity to assess liver damage in 8 wk control and
IL-6Rα∆/∆ mice fed on a NCD sacrificed at the indicated time points after a
100 mg/kg BW DEN injection (n=6). Displayed values are means ± S.E.M.;
*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control.
Mitochondria represent a central sensory organelle that can respond to DNA
damage by mitochondrial outer membrane permeabilization. This process is
tightly regulated by Bcl-2 protein family members such as Bcl-2, Bcl-XL, Mcl-1,
Bak or Bax [Brunelle & Letai, 2009]. To experimentally address whether increased
DEN-induced apoptosis in IL-6Rα∆/∆ mice is a consequence of enhanced mito-
chondrial apoptotic response, freshly isolated mitochondria from livers of naive
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control and IL-6Rα∆/∆ mice were incubated with increasing amounts of recombi-
nant Bax protein and the release of mitochondrial Cytochrome C was measured
by western blot analysis. These data demonstrated that mitochondria derived
from the livers of IL-6Rα∆/∆ mice were more susceptible to recombinant Bax
as indicated by the increased release of Cytochrome C in the cytosol compared
to control mice (Fig. 3.11A). Consistently, IL-6Rα-deficient hepatocytes demon-
strated concentration dependent cytosolic Cytochrome C levels in response to
DEN (Fig. 3.11B) as well as increased Cytochrome C at the mitochondria itself
(Fig. 3.11C).
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Figure 3.11: Cytochrome C release from mitochondria of control and IL-6Rα∆/∆ mice
(A) Cytochrome C release of isolated mitochondria after treatment with in-
creasing concentrations of recombinant Bax. Mitochondria were isolated
from naive 8 wk control and IL-6Rα∆/∆ mice fed a NCD. (B) Western blot
analysis using Cytochrome C and Actin antibodies of cytosolic extracts and
(C) western blot analysis using Cytochrome C and Complex II antibodies of
mitochondrial extracts from primary hepatocytes isolated from 8 wk control
and IL-6Rα∆/∆ mice that were treated with 0, 0.25, 0.5, 1 and 5 mM DEN for
48h in culture. Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤
0.01; ***, p ≤ 0.001 versus control. Data produced in collaboration with Jens
Seeger.
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The balance between anti- and pro-apoptotic members of the Bcl-2 protein fam-
ily regulates mitochondrial outer membrane permeabilization and the efflux of
Cytochrome C in response to cellular damage [Brunelle & Letai, 2009]. The pres-
ence of the anti-apoptotic Bcl-2 protein family members Mcl-1, Bcl-2 and Bcl-XL
at mitochondria has been shown to prevent Cytochrome C release, whereas pro-
apoptotic protein such as Bax and Bak stimulate Cytochrome C release [Brunelle
& Letai, 2009]. To investigate levels of these proteins at the mitochondria of tu-
mor bearing mice, western blot analysis of mitochondrial extracts, derived from
tumor livers of the different cohorts of mice, was performed. This analysis re-
vealed a reduced mitochondrial level of Mcl-1 in NCD fed IL-6Rα∆/∆ mice (Fig.
3.12A). Interestingly, upon HFD-feeding mitochondrial Mcl-1 protein levels were
restored to comparable levels in both control and IL-6Rα-deficient animals (Fig.
3.12A). Furthermore, levels of pro-apoptotic protein Bax were decreased in NCD
fed IL-6Rα∆/∆ mice, an effect which was blunted upon HFD feeding (Fig. 3.12A).
Notably, protein levels of Bcl-2, Bcl-XL and Bak were not altered between di-
ets and genotypes (Fig. 3.12A). Strikingly, qPCR analyses of liver cDNA of the
four different groups of mice revealed that the transcriptional levels of the corre-
sponding genes were largely unaltered (Fig. 3.12B) suggesting that the reduced
Mcl-1 content of mitochondria of IL-6Rα∆/∆ mice might be caused by a posttrans-
lational regulatory mechanism.
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Figure 3.12: Pro- and anti-apoptotic proteins in tumor livers of control and IL-6Rα∆/∆
mice
(A) Western blot analysis using Bcl-2, Bcl-XL, Mcl-1, Bak, Bax and Complex
II antibodies on isolated mitochondria from DEN-injected 8 mo control and
IL-6Rα∆/∆ mice. (B) qPCR of Bcl-2, Bcl-XL, Mcl-1, Bak and Bax on livers from
DEN-injected 8 mo control and IL-6Rα∆/∆ mice. (n=6). Displayed values are
means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control. Data
in A produced in collaboration with Jens Seeger.
Consistent with these data, immunohistochemistry of mouse liver sections demon-
strated that HFD feeding significantly increased Mcl-1 protein abundance in the
tumors independent from IL-6Rα signaling (Fig. 3.13A/B). The tumor-associated
Mcl-1 expression was further analyzed in dissected HCCs from livers of the dif-
ferent groups of mice by western blot analysis, demonstrating that Mcl-1 protein
was decreased in HCCs of lean IL-6Rα deficient mice compared to control tu-
mors, while HFD feeding increased Mcl-1 protein in HCCs of control as well as
IL-6Rα∆/∆ mice (Fig. 3.13C).
Hepatocyte apoptosis has been shown to result in compensatory proliferation
of adjacent hepatocytes to cause HCC development [Bisgaard et al., 1998]. IL-
6 is thought to contribute to hepatocyte proliferation and DEN administration
to male mice results in IL-6 production that depends on IKKβ in myleoid cells,
most likely the resident macrophages called Kupffer cells (KCs) Naugler et al.
[2007]; Cressman et al. [1996]. In addition to preventing IL-6 production, ablation
of IKKβ in myeloid cells prevents compensatory proliferation, one of the main
tumor promoting mechanisms [Maeda et al., 2005].
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Thus, proliferation of hepatocytes in response to DEN-induced apoptosis in
lean control and IL-6Rα∆/∆ mice (Fig. 3.13D) was compared. While hepatocyte
proliferation was significantly reduced in IL-6Rα-deficient animals without DEN
injection, DEN-induced compensatory proliferation of hepatocytes was compa-
rable between control and IL-6Rα∆/∆ mice as examined through quantitation of
Ki67-positive hepatocytes in livers of these mice (Fig. 3.13D).
Taken together, these experiments demonstrate that under NCD conditions,
loss of IL-6 signaling sensitizes hepatocytes to damage-induced apoptosis with-
out impairments in compensatory proliferation. However, under HFD condi-
tions, hepatocyte apoptosis is inhibited – even in the absence of IL-6Rα signaling.
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Figure 3.13: Mcl-1 level in tumor livers of control and IL-6Rα∆/∆ mice
(A) Representative Mcl-1-stained sections of livers from DEN-injected 8 mo
control and IL-6Rα∆/∆ mice. Dashed lines discriminate tumor and normal
liver tissue. (B) Quantitation of Mcl-1 in tumors of the big liver lobe from
DEN-injected 8 mo control and IL-6Rα∆/∆ mice. 0 = no Mcl-1, 1 = low Mcl-1,
2 = high Mcl-1 (C) Western blot analysis using Mcl-1 and Calnexin antibodies
on isolated tumors from DEN-injected 8 mo control and IL-6Rα∆/∆ mice. (D)
Quantitation of proliferating, Ki67 positive hepatocytes in liver sections from
8 wk control and IL-6Rα∆/∆ mice sacrificed at indicated time points upon in-
jection of 100 mg/kg BW DEN (n=3). Displayed values are means ± S.E.M.;
*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control. Data in A/B produced
in collaboration with Beate Straub.
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3.6 GSK-3β inhibition stabilizes Mcl-1 under obese conditions
in HCC development
The Mcl-1 protein comprises a N-terminal PEST domain that is responsible for its
short half-life. Among the numerous protein kinases that have been implicated in
the regulation of Mcl-1, glycogen synthase kinase 3 β (GSK-3β) is known to play
a pivotal role in controlling Mcl-1 protein stability [Maurer et al., 2006]. GSK-3β is
a serine/threonine protein kinase that, unlike most other protein kinases, is con-
stantly active but becomes inactivated upon phosphorylation at serine residue 9
(S9) [Cross et al., 1995]. Interestingly, inactivation of GSK-3β via phosphoryla-
tion at S9 increases stabilization and accumulation of Mcl-1 protein and thereby
prevents apoptosis [Ding et al., 2007].
To address the role of GSK-3β action in Mcl-1 protein stability during HCC
development, GSK-3β phosphorylation in the livers of DEN-treated control and
IL-6Rα∆/∆ mice upon either a NCD or HFD feeding was analysed. Remarkably,
GSK-3β was less phosphorylated at S9 and thus more active in livers of IL-6Rα∆/∆
mice upon NCD feeding (Fig. 3.14A/B), whereas total GSK-3β levels were unal-
tered (Fig. 3.14A/C). Interestingly, GSK-3β S9 phosphorylation was reconstituted
and Mcl-1 levels were increased in livers of IL-6Rα∆/∆ mice when exposed to
HFD feeding (Fig. 3.14A). Consistent with these observations, direct assessment
of GSK-3β kinase activity revealed significantly enhanced GSK-3β activity in liv-
ers of IL-6Rα∆/∆ mice fed a NCD but not a HFD (Fig. 3.14D).
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Figure 3.14: GSK-3β activity in tumor livers of control and IL-6Rα∆/∆ mice
(A) Western blot analysis using pGSK-3β, GSK-3β, Mcl-1, and AKT anti-
bodies on liver tissue from DEN-injected 8 mo control and IL-6Rα∆/∆ mice.
(B) Quantitation of pGSK-3β level and (C) GSK-3β level from A relative to
AKT levels. (D) Determination of GSK-3β activity in liver lysates from DEN-
injected 8 mo control and IL-6Rα∆/∆ mice (n=5). Displayed values are means
± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control.
Active GSK-3β has been previously demonstrated to regulate apoptosis through
expression of the BH3 only member PUMA that antagonizes Mcl-1 to sensitize
for apoptosis [Charvet et al., 2011]. Consistently, PUMA expression was 2-fold in-
creased in tumor livers of IL-6Rα∆/∆ mice but restored under obese conditions
(Fig. 3.15A). However, in the initial phase of tumor development PUMA ex-
pression was unchanged between genotypes (Fig. 3.15B). Of note, expression
of NOXA was unchanged between genotypes and diets (Fig. 3.15C).
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Figure 3.15: Puma and Noxa in tumor livers of control and IL-6Rα∆/∆ mice
(A) qPCR of Puma in liver of DEN-injected 8 mo male control and IL-6Rα∆/∆
mice (n=6). (B) qPCR of PUMA in livers of 8 wk control and IL-6Rα∆/∆ mice
after injection of 100 mg/kg DEN. (C) qPCR of Noxa in liver of DEN-injected
8 mo male control and IL-6Rα∆/∆ mice (n=6). Displayed values are means ±
S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control.
Next it was examined whether inactivation of GSK-3β is a downstream event
of IL-6 signaling that in turn stabilizes Mcl-1. Indeed, injection of IL-6 in control
mice resulted in marked phosphorylation of GSK-3β at S9 already 30 min post-
injection, which was paralleled by increased Mcl-1 protein levels (Fig. 3.16A). To
assess Mcl-1 stability and GSK-3β activity in the initial phase of tumor develop-
ment, control and IL-6Rα∆/∆ animals were injected with 100 mg/kg DEN and
Mcl-1 expression and GSK-3β phosphorylation were determined.
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While in control mice DEN injection stabilized Mcl-1 over time as a conse-
quence of GSK-3β inactivation, this response was largely blunted in IL-6Rα∆/∆
mice (Fig. 3.16B). Mcl-1 stabilization as well as GSK-3β phosphorylation in con-
trols corresponded with circulating IL-6 that peaked 8 h upon injection (Fig. 3.16C),
whereas Mcl-1 stability was maintained up to 24 h (Fig. 3.16B). However, PUMA
protein levels peaked in both genotypes 24h after DEN injection (Fig. 3.16B) indi-
cating that a GSK-3β independent mechanisms control PUMA expression. Thus,
abrogation of IL-6 signaling resulted in decreased Mcl-1 protein expression dur-
ing the early phases of DEN-induced liver tumorigenesis (Fig. 3.166B).
To directly address the role of GSK-3β regarding Mcl-1 stabilization in vivo,
control mice were injected with adeno-associated viral vectors (AAV) expressing
either GFP or a myc-tagged constitutive active GSK-3β variant (GSK-3βCA) har-
boring a serine to alanine substitution at position 9 of GSK-3β (S9A). Western blot
analysis using Mcl-1 antibody demonstrated that expression of GSK-3βCA in liv-
ers of control mice reduced Mcl-1 protein level after DEN injection (Fig. 3.16D),
similar to the observation in IL-6Rα∆/∆ (Fig. 3.16B). In line with the previous ex-
periment, PUMA levels failed to correlate with GSK-3β activity under acute DEN
conditions, although increased PUMA protein could be observed in non-injected
GSK-3βCA expressing livers (Fig. 3.16D).
These experiments therefore reveal that GSK-3β inactivation by phosphoryla-
tion at S9 is required during the initial phases of tumorigenesis to stabilize Mcl-1
protein levels.
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Figure 3.16: GSK-3β activity in initital phase of tumor development of control and IL-
6Rα∆/∆ mice
(A) Western blot analysis using pGSK-3β, Mcl-1, and AKT antibodies on liver
tissue from 8 wk control mice fed on NCD after i.v. injection of 50 ng IL-6.
(B)Western blot analysis using pGSK-3β, GSK-3β, Mcl-1, Puma and Calnexin
antibodies on liver tissue from 8 wk male control and IIL-6Rα∆/∆ mice fed on
NCD sacrificed at indicated time points after injection of 100 mg/kg DEN.
(C) Examination of serum IL-6 concentrations by ELISA taken from DEN-
injected 8 wk control mice at the indicated time points (n=10). (D) Western
blot analysis using pGSK-3β, GSK-3β, Mcl-1, Puma and Calnexin antibod-
ies on liver tissue from 8 wk control mice pre-infected with AAV8 viruses
expressing GFP or GSK-3βCA at indicated time points after injection of 100
mg/kg BW DEN. Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤
0.01; ***, p ≤ 0.001 versus control. Data in D produced in collaboration with
Claudia Wunderlich.
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GSK-3β S9 phosphorylation mainly occurs through the action of Phosphatidyli-
nositide 3-kinase (PI3K) signaling [Cross et al., 1995]. The PI3K/AKT pathway,
which transmits anti-apoptotic survival signals, is likely involved in mitigating
apoptosis in a substantial fraction of human tumors [Jiang & Liu, 2008; Cully
et al., 2006]. To determine the role of PI3K signaling in DEN-induced HCC devel-
opment of HFD fed mice, HCC-bearing HFD fed control mice were treated with
the specific PI3K inhibitor GDC-0941.
Accordingly, administration of GDC-0941 to tumor-bearing HFD fed mice re-
sulted in reactivation of GSK-3β (Fig. 3.17A). Consequently, Mcl-1 protein lev-
els were reduced in the livers of these mice when compared to HFD fed control
mice, though livers of NCD fed IL-6Rα∆/∆ mice still exhibited less Mcl-1 protein
(Fig. 3.17A). Furthermore, the reduction of Mcl-1 protein by inhibition of PI3K in
tumor-bearing HFD fed control mice resulted in an increase of TUNEL-positive
cells – a marker for apoptosis (Fig. 3.17B/C). Moreover, Ki67 staining of tumor
liver sections demonstrated that PI3K inhibition reduced hepatocyte prolifera-
tion (Fig. 3.17D/E). Importantly, the quantitative evaluation of apoptosis and
hepatocyte proliferation in livers of PI3K inhibitor-treated HFD fed control mice
revealed a significant increase in apoptosis and reduction in proliferation compa-
rable to that observed for NCD-fed IL-6Rα∆/∆ mice, which are protected against
HCC development.
However regardless of the result obtained from the pharmacological inhibition
of PI3K, the formation of PIP3 was similar in the cohorts of mice independent on
diet and genotype (Fig. 3.18A). Even downstream AKT activity was unaltered
in those groups of mice as examined on one hand by phosphorylation of AKT at
serine 473 (Fig. 3.18B/C) as well as by the ability of immunoprecipitated AKT to
phosphorylate a GSK-3β S9 including peptide on the other (Fig. 3.18D).
Thus, PI3K/AKT signaling is active but not altered in the absence of IL-6Rα
signaling in HCC development independent on dietary condition.
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Figure 3.17: PI3K inhibition in tumor bearing control and IL-6Rα∆/∆ mice
(A) Western blot analysis using pGSK-3β, Mcl-1 and Calnexin antibodies on
liver tissue from DEN-injected 8 mo control and IL-6Rα∆/∆ mice treated with
GDC-0941 or with vehicle. (B) Quantitation of C (n=4).(C) TUNEL stainings
of tumor liver sections from DEN-injected 8 mo IL-6Rα∆/∆ and control mice
treated with or without GDC-0941.(D)Quantitation E (n=4). (E)Ki67 staining
of tumor liver sections from DEN-injected 8-mo IL-6Rα∆/∆ and control mice
treated with or without GDC-0941. Displayed values are means ± S.E.M.; *,
p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control.
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Figure 3.18: PI3K pathway in tumor bearing control and IL-6Rα∆/∆ mice
(A)Determination of PIP3 concentration in liver lysates from DEN-injected
8 mo control and IL-6Rα∆/∆ mice examined by PI3K activity assay (n=6).
(B) Western blot analysis of liver lysates from DEN-injected 8 mo control
and IL-6Rα∆/∆ mice using pAKT and Calnexin antibodies. (C) Quantitation
of pAKT level from B relative to Calnexin (n=6). (D) AKT kinase activity
assay of liver lysates from DEN-injected 8 mo control and IL-6Rα∆/∆ mice.
Immunoprecipitated AKT was incubated in a reaction with GSK-3β peptide.
Western blots of reaction and input using pGSK-3β and AKT antibodies. Dis-
played values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001
versus control.
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3.7 Obesity and IL-6 controlled expression of PP-1α and
Mule synergize to stabilize Mcl-1
Hence alteration of PI3K/AKT activity in lean IL-6Rα-deficient animals failed to
explain increased GSK-3β action, the expression levels of protein phosphatase 1
α (PP-1α) that catalyzes the reverse reaction, namely GSK-3β dephosphorylation
at S9 were examined. Strikingly, expression levels of PP-1α were more than 2-
fold increased in IL-6Rα-deficient mice in the DEN-induced HCC protocol when
compared to controls (Fig. 3.19A). Transcriptional control of IL-6 regulated gene
expression is mainly mediated through the transcription factor Stat-3, whose ac-
tivation was reduced in lean IL-6Rα∆/∆ mice in acute as well as chronic DEN
experiments (Fig. 3.19B/C). Evidently, not only the restored hepatic Stat-3 activa-
tion in obese IL-6Rα∆/∆ mice occured independent of IL-6 but also the remaining
DEN-induced Stat-3 activation in lean IL-6Rα∆/∆ mice, thus indicating another
obesity- and/or DEN-induced factor that activates Stat-3 in the absence of IL-6Rα
(Fig. 3.19B/C).
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Figure 3.19: PP-1α expression and Stat-3 activation in control and IL-6Rα∆/∆ mice
(A)qPCR of PP-1CA in liver of DEN-injected 8 mo male control and IL-
6Rα∆/∆ mice (n=6). (B) Western blot analysis using pStat-3 and GSK-3β anti-
bodies on liver tissue from 8 wk control and IIL-6Rα∆/∆ mice after injection
of 100 mg/kg DEN. (C) Western blot analysis using pStat-3 and Calnexin an-
tibodies on liver tissue from DEN-injected 8 mo control and IL-6Rα∆/∆ mice.
Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001
versus control.
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Careful investigation of the PP-1α promoter revealed a conserved Stat-3 bind-
ing site between mouse and human upstream of transcriptional initiation (Fig.
3.20A). To address whether this motif is bound by phosphorylated Stat-3 in re-
sponse to IL-6, chromatin immunoprecipitation (ChIP) experiments of basal and
IL-6-stimulated HepG2 cells were performed that demonstrated activated Stat-3
at this site under basal conditions but IL-6 stimulation increased the presence of
Stat-3 at this motif (Fig. 3.20B). To determine whether PP-1α is a direct IL-6 target
in vivo and how expression is affected by IL-6-induced Stat-3 activation, a cohort
of C57/BL6 mice were injected with IL-6 and relative hepatic expression of PP-1α
was examined in a time frame of 240 min after IL-6 injection. PP-1α expression
was significantly reduced upon IL-6 treatment 60 min post injection and progres-
sively declined up to 240 min, indicating that PP-1α is a transcriptional target for
IL-6-induced repression (Fig. 3.20C). To examine whether PP-1α inhibition is suf-
ficient to stabilize Mcl-1 protein in acute DEN injection experiments in vivo, the
specific PP-1α inhibitor okadaic acid (OA) was applied 1 hour before DEN injec-
tion in lean control and in IL-6Rα-deficient animals and the S9 phosphorylation of
GSK-3β was investigated as well as Mcl-1 protein abundance. Expectedly, PP-1α
inhibition resulted in the persistent phosphorylation of GSK-3β in both IL-6Rα-
deficient and control mice (Fig. 3.20D). However, hepatic Mcl-1 protein levels in
IL-6Rα-deficient mice were still reduced when PP-1α was inhibited (Fig. 3.20D),
hinting to another synergistic pathway independent of PP-1α and GSK-3β that
destabilizes Mcl-1 in lean IL-6Rα-deficient mice.
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Figure 3.20: PP-1 promoter analysis in control and IL-6Rα∆/∆ mice
(A) llustration of PP-1CA promoter region for ChIP analysis. Putative Stat-3
binding sites are indicated by vertical black lines and include matrix sim-
ilarity (above) and human and murine sequences with base pair precision
(below). Capitals in the sequence indicate the core sequence, black letters
a ci-value > 60. Oligos (5hPP1CAChip/3hPP1CAChip) used for PCR am-
plification are indicated by open triangles outside of the expected fragment.
(B) ChIP using RNA PolII, IgG and pStat-3 antibodies on sonicated DNA
isolated from HepG2 cells stimulated with 200ng/ml IL-6 for 45 min using
oligos 5hPP1CAChip and 3hPP1CAChip to examine PP-1CA promoter. (C)
qPCR of PP-1CA in liver of 8 wk control mice fed on NCD after i.v. injection
of 50 ng IL-6 (n=5). (D) Western blot analysis using pGSK-3β, Mcl-1, and Cal-
nexin antibodies on liver tissue from 8 wk old male control and IL-6Rα∆/∆
mice fed on NCD pre-treated with 750 ng OA/g BW 1 hr before injection of
a 100 mg/kg BW DEN dose. Displayed values are means ± S.E.M.; *, p ≤
0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control. Data in A/B produced in
collaboration with Justus Ackermann
Recently, GSK-3β-phosphorylated Mcl-1 has been shown to be recognized by
either Mcl-1 ubiquitin ligase E3 (Mule) or the SKP1-cullin-F-box WD repeat-C´
containing protein 7 (SCF-FBW7) E3 ligase both of which ligate polyubiquitin
chains to Mcl-1 that lead to its proteasomal degradation [Wertz et al., 2011; Zhong
et al., 2005]. In order to determine whether the expression of these E3 ligases
correlate with Mcl-1 levels in lean and obese control and IL-6Rα∆/∆ mice, qPCR
analyses of tumor livers from these mice was performed.
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Strikingly, while a 2-fold elevated expression of Mule could be observed in lean
IL-6Rα∆/∆ mice compared to lean controls, Mule expression was significantly
reduced under obese conditions in mice of both genotypes (Fig. 3.21A). Inter-
estingly, comparison of the expression levels of the subunits FBW7 and cullin 1
(Cul-1) of the SCF-FBW7 complex to Mule expression revealed a 20-fold lower
FBW7 expression and 5-fold lower Cul-1 expression indicating that Mule rather
than the SCF-FBW7 E3 ligase complex might play a role in liver carcinogenesis by
interfering with Mcl-1 protein stability (Fig. 3.21A). Consistently, examination of
Mule expression in acute DEN injection experiments revealed an impaired sup-
pression of Mule IL-6Rα∆/∆ mice in response to DEN when compared to controls
(Fig. 3.21B).
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Figure 3.21: Mule expression in control and IL-6Rα∆/∆ mice
(A) qPCR of Mule, FBW7 and Cul1 in liver of DEN-injected 8 mo male control
and IL-6Rα∆/∆ mice (n=6). (B) qPCR of Mule in liver of 8 wk control mice
fed on NCD after injection of 100 mg/kg BW DEN (n=5). Displayed values
are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control.
This result support the assumption that Mule expression is directly inhibited
by IL-6 and that impaired suppression of Mule upon IL-6Rα deficiency during
HCC initiation might result in increased Mcl-1 protein turnover and apoptosis.
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In line with these experiments that suggest an important role of IL-6-induced
Stat-3 in the inhibition of Mule expression, the promoter region of Mule was anal-
ysed and two conserved Stat-3 binding motifs between mouse and human were
identified within a region upstream of Mule transcriptional initiation (Fig. 3.22A).
Chip experiments of basal and IL-6-stimulated HepG2 cells revealed active Stat-3
bound to the Mule promoter at the basal state, whereas IL-6 stimulation increased
Stat-3 binding to these sites (Fig. 3.22B). Of note, binding of activated Stat-3 to
the Stat-3 motifs in the Mule promoter was specific as using oligos more distal
to these sites revealed still actively bound RNA pol II but not active Stat-3 (Fig.
3.22C).
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Figure 3.22: ChIP experiments with Mule promoter
(A) Ilustration of Huwe1/Mule promoter region for ChIP analysis. Putative
Stat-3 binding sites are indicated by vertical black lines and include matrix
similarity (above) and human and murine sequences with basepair precision
(below). Capitals in the sequence indicate the core sequence, black letters
a ci-value > 60. Oligos (5hMULEChip/3hMULEChip) used for PCR ampli-
fication are indicated by open triangles outside of the expected fragment.
(B) ChIP using RNA PolII, IgG and p-Stat3 antibodies on sonicated DNA
isolated from HepG2 cells stimulated with 200 ng/ml IL-6 for 45 min us-
ing oligos 5hMULEChip and 3hMULEChip to examine Mule promoter. (C)
ChIP using RNA PolII, IgG and pStat-3 antibodies on sonicated DNA iso-
lated from HepG2 cells stimulated with 200 ng/ml IL-6 for 45 min using oli-
gos 5hMULEUSChIP and 3hMULEUSChIP to examine Mule promoter. Dis-
played values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001
versus control. Data produced in collaboration with Justus Ackermann
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To directly clarify whether Mule expression is subjected to IL-6-induced re-
pression, 1000 bp upstream of Mule exon 1 that contains the promoter including
regulatory elements was cloned in front of a firefly luciferase and this construct
was transfected into HepG2 cells. Examination of luciferase activity revealed sig-
nificantly 40% reduced Mule promoter activity upon IL-6 stimulation, whereas
luciferase activity substantially increased when transfected cells were incubated
in the presence of the Stat-3 inhibitor STATTIC (Fig. 3.23A). Accordingly, inves-
tigation of mice expressing a constitutive active Stat-3 variant in hepatocytes re-
vealed a 40% reduced Mule expression similar to the in vitro findings (Fig. 3.23B).
Therefore, these analyses reveal that expression of the ubiquitin ligase Mule is
regulated by IL-6- and obesity-controlled Stat-3 activation that impacts on Mcl-1
stability and thus alters apoptosis sensitivity.
In order to verify the mechanism of Mcl-1 stabilization in vitro, primary hep-
atocytes derived from control and IL-6Rα∆/∆ animals were stimulated with 50
ng/ml IL-6 in a time frame and Western Blot analysis was performed. This analy-
sis revealed that IL-6 treatment increased Mcl-1 protein, inhibited GSK-3β activity
and repressed Mule expression in control hepatocytes, whereas these processes
were not present in IL-6Rα-deficient cells (Fig. 3.23C). To prove the mechanism
directly in tumor cells, Hep3B cells were stimulated with IL-6 for 1, 4 and 8 h.
While IL-6 treatment increased Mcl-1 protein, this effect was blunted when IL-
6Rα action was inhibited through the supplementation of a neutralizing antibody
(Fig. 3.23D). Similar to the in vivo data, IL-6 treatment inhibited GSK-3β activity
and repressed Mule expression, whereas these processes were not present when
IL-6Rα action was neutralized (Fig. 3.23D). Importantly, supplementation of IgG
control antibody failed to affect IL-6-induced Mcl-1 stabilization.
In summary, these data clearly prove the key role of IL-6 mediated inhibition
of Mule expression in the development of HCC.
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Figure 3.23: Mule promoter analysis in control and IL-6Rα∆/∆ mice
(A) Luciferase activity of lysates obtained from HepG2 cells transfected with
pTEMule-Luc and pRL-Null stimulated with IL-6 and/or preincubated with
20 µM STATTIC (n=9/stimulation). (B) qPCR of Mule in livers of 8 wk con-
trol and constitutive active Stat-3-C mice (n=4). (C) Western blot analysis
using pStat-3, Mcl-1, AKT, Mule, pGSK-3β and Calnexin antibodies of pri-
mary hepatocytes derived from control and IL-6Rα∆/∆ mice stimulated with
50 ng/ml IL-6 for the indicated time points. (D) Western blot analysis using
pStat-3, Mcl-1, AKT, Mule, pGSK-3β and Calnexin antibodies of Hep3B cells
stimulated with 50 ng/ml IL-6 and IL-6 plus 5 µg/ml neutralizing IL-6Rα
antibody or control antibody. Displayed values are means ± S.E.M.; *, p ≤
0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control. Data in A/C produced in
collaboration with Justus Ackermann
3 Results 82
Increased Mcl-1 levels have previously been reported in a subset of human
HCC [Fleischer et al., 2006], however the correlation between Mcl-1 and Mule has
never been addressed in HCC. Therefore, human HCC samples were examined
in immunohistochemistry using anti-Mule and anti-Mcl-1 antibodies revealing
that Mcl-1 expression in human HCC negatively correlated with Mule expression.
Cases that showed no steatosis (#1, #2), steatosis (#3) and a steatohepatitic pattern
(#4, #5) were classified by visible lipid inclusions into the liver (Fig. 3.24). While,
the non-steatotic cases #1, #2 revealed almost no Mcl-1 expression and high Mule
expression, the steatohepatitic HCC cases #4, #5 exhibited the most prominent
Mcl-1 expression accompanied with a reduction in Mule expression (Fig. 3.24).
Collectively, the experiments demonstrate that obesity and IL-6 signaling syn-
ergize to affect the protein stability of the Bcl-2 family member Mcl-1 via GSK-3β
inhibition and repression of Mule expression to inhibit the mitochondrial apop-
totic pathway during HCC development.
Mcl-1
Mule
# 1 # 2 # 3 # 4 # 5
Figure 3.24: Correlation between Mule and Mcl-1 level in human HCC
(A) Mcl-1 and Mule stainings of 5 different human HCC sections. Data pro-
duced in collaboration with the group of Lukas Heukamp
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3.8 Compensatory effects of IL-6 type cytokines and
receptors
3.8.1 HFD causes obesity in control, IL-6Rα∆/∆ and gp130L−KO mice
While it is certainly not clear which factor in obesity compensates for IL-6Rα de-
ficiency in HCC development, another IL-6 type cytokine or receptor might ac-
count for this observation. The common feature of all IL-6 type cytokine recep-
tors is the signaling transducing receptor unit glycoprotein 130 (gp130) [Zhang
et al., 1994]. To determine if another pathway of IL-6 type cytokines is involved
in the development of HCC conditional gp130-deficient mice were generated
allowing the cell type specific inactivation of gp130 in hepatocytes. Therefore,
gp130 f l/ f l mice were crossed to mice expressing the Cre recombinase under the
control of both the mouse albumin regulatory elements and the α-fetoprotein en-
hancers (AlfpCre transgene) [Kellendonk et al., 2000; Betz et al., 1998]. These mice
were further intercrossed with siblings leading to hepatocyte specific deletion of
gp130 (gp130L−KO). To investigate whether gp130-deficiency in hepatocytes af-
fects HCC development under normal and obese conditions, male gp130L−KO
mice were injected with 25 mg/kg BW DEN i.p. at 15 days of age and separated
after weaning in cohorts fed either a NCD or HFD for 8 month.
As expected, HFD feeding significantly increased body weight in gp130L−KO
compared to mice upon NCD feeding, whereas no differences could be detected
in comparision with IL-6Rα∆/∆ and control mice neither upon NCD nor HFD
feeding (Fig. 3.25). These data demonstrate that HFD exposure causes similar
levels of obesity in both control, IL-6Rα∆/∆ and gp130L−KO mice.
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Figure 3.25: Body weight of control, IL-6Rα∆/∆ and gp130L−KO mice
(A) Weight determination of 8 mo control, IL-6Rα∆/∆ and gp130L−KO mice
(n=15) injected with 25 mg/kg BW DEN at 15 days of age and exposed to
NCD or HFD after weaning. Displayed values are means ± S.E.M.; *, p ≤
0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control.
3.8.2 Inactivation of gp130 in hepatocytes protected against DEN-induced
HCC development even under obese conditions
To determine if another pathway of IL-6 type cytokines is involved in the de-
velopment of HCC, tumor development in 8 month-old DEN-treated gp130L−KO
mice that had been exposed to either a NCD or HFD feeding was investigated
by visual inspection and compared to control and IL-6Rα∆/∆ mice. Similar to IL-
6Rα∆/∆ mice, gp130L−KO mice upon NCD feeding developed significantly less
macroscopically visible liver tumors compared to control mice (Fig. 3.26A/B).
90% of the tumors were smaller than 2 mm (Fig. 3.26C) whereas 10% reached
a size of more than 2 mm (Fig. 3.26D). Surprisingly, in contrast to control and
IL-6Rα∆/∆ mice, obesity did not increase tumor burden in gp130L−KO mice (Fig.
3.26A/B).
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Figure 3.26: Turmor burden macroscopic in control, IL-6Rα∆/∆ and gp130L−KO mice
(A) Livers of 8 mo control, IL-6Rα∆/∆ and gp130L−KO mice injected with 25
mg/kg BW DEN at 15 days of age. (B) Quantitation of macroscopic tumor
multiplicity determined by visual inspection in DEN-injected 8 mo control,
IL-6Rα∆/∆ and gp130L−KO mice (n=15). (C) Enumeration of tumor number
for < 2 mm and (D) > 2 mm as determined by visual inspection of DEN-
injected 8 mo control, IL-6Rα∆/∆ and gp130L−KO mice (n=15). Displayed
values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus
control.
Histological investigation of HE-stained liver sections confirmed that NCD-fed
gp130L−KO mice revealed significantly decreased number of HCC foci when com-
pared to NCD-fed control mice, similar to IL-6Rα∆/∆ mice (Fig. 3.27A). However,
this difference was not as large as observed upon macroscopic inspection. Fur-
thermore, tumor size was significantly decreased in gp130L−KO mice upon NCD
feeding compared to control mice, but comparable to IL-6Rα∆/∆ mice (Fig. 3.27B).
3 Results 86
HFD data were not available at this point.
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Figure 3.27: Turmor burden microscopic in control, IL-6Rα∆/∆ and gp130L−KO mice
(A) Quantitation of tumor number per 2 lobules counted on liver sections
from 8 mo control, IL-6Rα∆/∆ and gp130L−KO mice (n=15). (B) Quantitation
of tumor size measured in the big liver lobe of DEN-injected 8 mo control, IL-
6Rα∆/∆ and gp130L−KO mice (n=15). Displayed values are means ± S.E.M.;
*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control. Data produced in
collaboration with Beate Straub.
The extent of inflammation, assessed by quantitation of infiltrating immune
cells, was significantly reduced in livers of gp130L−KO mice compared to con-
trol mice upon NCD feeding, but similar to IL-6Rα∆/∆ mice (Fig. 3.28A). Liver
steatosis was determined in control, IL-6Rα∆/∆ and gp130L−KO mice. Livers of
gp130L−KO mice fed a NCD revealed a significantly reduced extent of steatosis
compared to control mice, similar to L-6Rα∆/∆ mice (Fig. 3.28B). Additionally,
counting of necrotic hepatocytes per two lobules revealed a significant decrease
in gp130L−KO mice compared to control mice upon NCD feeding (Fig. 3.28C). As
fibrosis is also connected to the development of liver cancer, the extent of fibro-
sis was determined by score. By comparison no significant alteration could be
detected between the genotypes (Fig. 3.28D).
Taken together, these data demonstrate that gp130-deficiency in hepatocytes
protected against DEN-induced HCC development even under obese conditions.
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Figure 3.28: Liver status of control, IL-6Rα∆/∆ and gp130L−KO mice
(A) Quantitation of inflammation measured in the big liver lobe of DEN-
injected 8 mo control, IL-6Rα∆/∆ and gp130L−KO. 1 = mild inflammation
(mild portal inflammation, 3-5 single cell necrosis, no grouped necrosis); 2 =
moderate inflammation (moderate portal inflammation, 6-9 single cell necro-
sis, 1 grouped necrosis); 3 = severe inflammation (severe portal inflamma-
tion, more than 10 single cell necrosis, more than 1 grouped necrosis) (n=15).
(B) Quantitation of steatosis measured in the big liver lobe of DEN-injected
8 mo control, IL-6Rα∆/∆ and gp130L−KO. 1 = 0 - 10%; 2 = 11 - 50 %; 3 = above
50 % (C) Quantitation of necrotic cells measured in the big liver lobe of DEN-
injected 8 mo control, IL-6Rα∆/∆ and gp130L−KO. (D) Quantitation of fibrosis
measured in the big liver lobe of DEN-injected 8 mo control, IL-6Rα∆/∆ and
gp130L−KO. 1 = increased portal connective tissue; 2 = early formation of
septa (n = 15). Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤
0.01; ***, p≤ 0.001 versus control. Data produced in collaboration with Beate
Straub.
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3.8.3 No compensation for IL-6Rα deficiency by IL-6 type cytokines in HCC
development upon HFD feeding
The gp130 subunit is part of every member of the IL-6 type cytokine receptor fam-
ily [Zhang et al., 1994]. To investigate which IL-6 type cytokine or receptor could
compensate for IL-6Rα deficiency in HCC development on HFD, expression of
different IL-6 type cytokines and receptors were investigated (Fig. 3.29A-D),
such as IL-6, IL-11, oncostatin M (OSM), ciliary neurotrophic factor (CNTF), IL-
30, leukemia inhibitory factor (LIF), cardiothrophin 1(CTF-1) and cardiotrophin-
like cytokine factor 1 (CTCF-1) (Fig. 3.29A/B). As expected, IL-6 expression
was increased in IL-6Rα∆/∆ mice upon HFD feeding compared to control mice
(Fig. 3.29A). Furthermore, OSM revealed a significant decrease in IL-6Rα∆/∆ mice
upon HFD feeding compared to control mice (Fig. 3.29A), whereas CTF-1 exhib-
ited a significant decrease in control mice upon HFD feeding compared to control
mice upon NCD feeding (Fig. 3.29B).
Investigation of the different IL-6 type cytokine receptors, IL-6Rα, IL-11R, OSMR,
CNTFR, IL-27R, Epstein-Barr virus induced gene 3 (EBI-3), LIFR and gp130, re-
vealed a wide range of alterations between the diets and genotypes (Fig. 3.29C/D).
As expected IL-6Rα was significantly decreased in IL-6Rα∆/∆ mice both upon
NCD and HFD feeding (Fig. 3.29C). Furthermore, the IL-11R, whose structure is
very similar to the IL-6Rα, exhibited a significantly increase in IL-6Rα∆/∆ mice
upon NCD feeding compared to control mice upon NCD feeding as well as to
IL-6Rα∆/∆ mice upon HFD feeding (Fig. 3.29C). Similar to OSM, the OSMR was
significantly increased in IL-6Rα∆/∆ mice upon HFD feeding compared to con-
trol mice upon HFD feeding as well as to IL-6Rα∆/∆ upon NCD feeding (Fig.
3.29C). The CNTFR revealed a significant decrease upon HFD feeding but no al-
terations between genotypes (Fig. 3.29C). EBI-3 was significantly increased in
control mice upon HFD feeding whereas IL-6Rα∆/∆ displayed only a tendency to
increased EBI-3 upon HFD feeding compared to NCD feeding (Fig. 3.29D). Simi-
lar to CNTFR, LIFR was decreased upon HFD feeding both in control as well as in
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IL-6Rα∆/∆ mice (Fig. 3.29D). Surprisingly, gp130 revealed a significant decrease
in IL-6Rα∆/∆ mice upon HFD feeding compared to mice upon NCD feeding (Fig.
3.29D).
In summary, determination of IL-6 type cytokines and receptors expression in
tumor livers of control and IL-6Rα deficient animals under both dietary condi-
tions failed to directly clarify which factor compensates for IL-6Rα-deficiency in
HCC development upon HFD feeding and needs further investigation.
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Figure 3.29: IL-6 type cytokines and receptors in tumor livers of control and IL-6Rα∆/∆
mice
(A) qPCR of IL-6, IL-11, OSM and CNTF in livers from DEN-injected 8 month
control and IL-6Rα∆/∆ mice (n=6). (B) qPCR expression of IL-30, LIF, CTF-
1 and CLCF-1 in livers from DEN-injected 8 month control and IL-6Rα∆/∆
mice (n=6). (C) qPCR of IL-6R, IL-11R, OSMR and CNTFR in livers from
DEN-injected 8 month control and IL-6Rα∆/∆ mice (n=6). (D) qPCR of IL-
27R, EBI-3, LIFR and gp130 in livers from DEN-injected 8 month control and
IL-6Rα∆/∆ mice (n=6). Displayed values are means ± S.E.M.; *, p ≤ 0.05; **,
p ≤ 0.01; ***, p ≤ 0.001 versus control.
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3.9 The cell-type specific role of the IL-6Rα in the
development of HCC
The expression of the IL-6Rα is restricted to certain types of cells including hep-
atocytes, myeloid cells and T cells. To investigate the cell specific role of IL-6
signaling in the development of hepatocellular carcinoma, conditional IL-6Rα-
deficient mice were generated. Therefore IL-6Rα f l/ f l mice were crossed to mice
expressing the Cre recombinase under the control of both the mouse albumin
regulatory elements and the α-fetoprotein enhancers (AlfpCre transgene), under
the control of the murine lysozyme M gene (LysMcre) and under the control of
the CD4 enhancer/ promoter/silencer, respectively [Wunderlich et al., 2010; Lee
et al., 2001; Kellendonk et al., 2000; Clausen et al., 1999]. These mice were further
intercrossed with siblings leading to hepatocyte specific (IL-6RαL−KO), myeloid
specific (IL-6RαM−KO) and T cell specific (IL-6RαT−KO) deletion of the IL-6Rα. IL-
6Rα f l/ f l mice served as controls for all groups throughout experiments.
To investigate the cell-type specific role of IL-6 signaling in the development of
hepatocellular carcinoma under normal and obese conditions, male IL-6Rα f l/ f l,
IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO mice were treated with
DEN as described before and separated after weaning in cohorts fed either a
NCD or HFD for 8 month. To examine whether IL-6Rα deficiency in different
cell types has an impact on metabolic or inflammatory state, different parameters
were measured.
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3.9.1 Less effects on body weight through HFD feeding in IL-6RαL−KO,
IL-6RαM−KO and IL-6RαT−KO mice
Upon NCD feeding no differences in body weight could be detected between
the genotypes (Fig. 3.30A). In contrast to control and IL-6Rα∆/∆ mice upon HFD
feeding, no differences could be detected in IL-6RαL−KO, IL-6RαM−KO and IL-
6RαT−KO mice between NCD and HFD feeding (Fig. 3.30A). To determine the
extent of lipid burden in the blood, cholesterol and triglyceride level in the serum
were measured (Fig. 3.30B/C). Cholesterol measurement revealed similar levels
in all genotypes upon NCD feeding before DEN treatment (Fig. 3.30B). No al-
teration in Cholesterol levels could be detected in IL-6RαL−KO, IL-6RαM−KO and
IL-6RαT−KO mice after DEN treatment compared to non-treated animals whereas
Cholesterol levels significantly increased in control and IL-6Rα∆/∆ upon NCD
feeding (Fig. 3.30B). HFD data were not available at this point. Triglyceride levels
were completely unaltered between treated and non-treated mice and between
genotypes (Fig. 3.30C).
Taken together, these data demonstrate that HFD exposure causes similar lev-
els of obesity in control and IL-6Rα∆/∆ mice upon DEN induction, but less effects
of HFD feeding in IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO mice.
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Figure 3.30: Metabolic status of control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-
6RαT−KO mice
(A) Weight determination of 8 mo DEN-injected control, IL-6Rα∆/∆, IL-
6RαL−KO, IL-6RαM−KO and IL-6RαT−KO mice (n=15) (B) Examination of
serum cholesterol level and (C) serum triglyceride level of untreated (-) or
DEN-injected (+) 8 mo control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-
6RαT−KO mice (n=6). Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p
≤ 0.01; ***, p ≤ 0.001 versus control.
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3.9.2 IL-6RαT−KO mice are protected against DEN-induced HCC even on
HFD
In the next step tumor development in 8 month old DEN-treated control, IL-
6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO mice that had been exposed
to either a NCD or HFD were investigated by visual inspection. IL-6RαL−KO mice
on NCD revealed a tendency for decreased tumor numbers compared to con-
trol mice, whereas IL-6RαM−KO mice had no differences in tumor burden upon
NCD feeding (Fig. 3.31A/B). Surprisingly, IL-6RαT−KO mice upon NCD feed-
ing exhibited almost the same protection for tumor development as IL-6Rα∆/∆
on NCD (Fig. 3.31A/B). In line with previous experiments, obesity increased tu-
mor burden in control mice, IL-6Rα∆/∆, IL-6RαL−KO and IL-6RαM−KO mice (Fig.
3.31A/B). Only IL-6RαT−KO mice were almost protected against DEN-induced
HCC even upon HFD feeding (Fig. 3.31A/B). In contrast to IL-6Rα∆/∆ mice, IL-
6RαT−KO mice revealed no significant difference in tumor number <2mm upon
NCD feeding whereas upon HFD feeding IL-6RαT−KO mice had less tumors <2mm
compared to control mice, similar to IL-6Rα∆/∆ mice (Fig. 3.31C). Additionally,
IL-6RαT−KO mice exhibited significantly less tumors >2mm upon NCD feeding
as well as upon HFD feeding compared to control mice (Fig. 3.31D).
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Figure 3.31: Turmor burden macroscopic in control, IL-6Rα∆/∆, IL-6RαL−KO, IL-
6RαM−KO and IL-6RαT−KO mice
(A) Livers of 8 mo control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-
6RαT−KO mice injected with 25 mg/kg BW DEN at 15 days of age. (B) Quan-
titation of macroscopic tumor multiplicity determined by visual inspection
in DEN-injected 8 mo ccontrol, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-
6RαT−KO mice (n=15). (C) Enumeration of tumor number for < 2 mm (D) and
> 2 mm as determined by visual inspection of DEN-injected 8 mo control, IL-
6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO mice (n=15). Displayed
values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus
control.
Hepatocyte steatosis can sequentially lead to the development of liver damage
and steatohepatitis which are forerunners of HCC development. As an indirect
indicator of liver damage, the activity of the liver AST and ALT were measured
in control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO mice on NCD
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before and after DEN treatment (Fig. 3.32A/B). AST and ALT level were not sig-
nificantly different in the serum of control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO
and IL-6RαT−KO mice before DEN treatment (Fig. 3.32A/B). After DEN treatment
serum AST level significantly increased to the same extent in control, IL-6Rα∆/∆,
IL-6RαM−KO and IL-6RαT−KO mice, whereas IL-6RαL−KO revealed a significant
increase after DEN treatment compared to other genotypes after DEN treatment
(Fig. 3.32A). No alteration of serum ALT level could be observed between geno-
types after DEN treatment (Fig. 3.32B).
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Figure 3.32: Liver damage of control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-
6RαT−KO mice
(A) Investigation of AST and (B) ALT activity in serum of untreated (-) or
DEN-injected (+) 8 mo control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-
6RαT−KO mice (n=6). Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p
≤ 0.01; ***, p ≤ 0.001 versus control.
Histological investigation of HE-stained liver sections confirmed that NCD-
fed IL-6RαL−KO and IL-6RαM−KO mice had no significant difference in number of
HCC foci when compared to NCD-fed control mice (Fig. 3.33A). Strikingly, HFD
feeding increased the carcinogenic capability of DEN in IL-6RαM−KO animals but
not in IL-6RαL−KO mice (Fig. 3.33A). Furthermore decreased number of foci in IL-
6RαT−KO mice could not be confirmed by this analysis (Fig. 3.33A). HFD data for
IL-6RαT−KO mice were not available at this point. Determination of tumor size
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exhibited significant increase of foci size in IL-6RαL−KO and IL-6RαM−KO mice
upon NCD feeding compared to control mice, whereas IL-6RαT−KO mice revealed
no alterations in tumor size compared to control mice upon NCD feeding (Fig.
3.33B). Strikingly, tumor size in control, IL-6Rα∆/∆, IL-6RαM−KO and IL-6RαT−KO
mice did not change upon HFD feeding compared to NCD feeding, whereas foci
size significantly decreased in IL-6RαL−KO mice upon HFD feeding compared to
NCD feeding (Fig. 3.33B).
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Figure 3.33: Turmor burden microscopic in control, IL-6Rα∆/∆, IL-6RαL−KO, IL-
6RαM−KO and IL-6RαT−KO mice
(A) Quantitation of tumor number per 2 lobules counted on liver sections
from 8 mo control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO
mice (n=15). (B) Quantitation of tumor size measured in the big liver lobe
of DEN-injected 8 mo control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-
6RαT−KO mice (n=15). Displayed values are means ± S.E.M.; *, p ≤ 0.05; **,
p ≤ 0.01; ***, p ≤ 0.001 versus control. Data produced in collaboration with
Beate Straub.
To assess the extent of inflammation, infiltrating immune cells were quanti-
tated. This analysis revealed a significant reduced inflammation in livers of IL-
6RαT−KO mice upon NCD feeding compared to control mice upon NCD feeding,
similar to IL-6Rα∆/∆ mice (Fig. 3.34A), whereas IL-6RαL−KO and IL-6RαM−KO
mice exhibited no significant differences. Upon HFD feeding liver inflammation
significantly increased in control, IL-6Rα∆/∆ and IL-6RαL−KO animals but not in
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IL-6RαM−KO mice (Fig. 3.34A). HFD data of IL-6RαT−KO mice were not available
at this point.
As mentioned before, HFD feeding was observed to induce hepatocyte steato-
sis that can result in HCC development. Similar to IL-6Rα∆/∆ mice, livers of
IL-6RαT−KO mice fed a NCD revealed a significantly reduced extent of steatosis
compared to control mice whereas IL-6RαL−KO and IL-6RαM−KO mice exhibited
no alteration (Fig. 3.34B). In contrast to IL-6Rα∆/∆ mice, the extent of steatosis
did not increase both in IL-6RαL−KO and IL-6RαM−KO mice upon HFD feeding
compared to NCD fed mice (Fig. 3.34B). HFD data of IL-6RαT−KO mice were not
available at this point.
Counting of necrotic hepatocytes per two lobules revealed significant reduction
in IL-6RαT−KO mice on NCD compared to control mice upon NCD feeding, con-
trary to IL-6Rα∆/∆ mice (Fig. 3.34C). Similar to inflammation status upon HFD
feeding, necrotic cells increased in IL-6Rα∆/∆, IL-6RαL−KO and IL-6RαM−KO mice
but not in IL-6RαM−KO mice compared to HFD feeding (Fig. 3.34C). HFD data of
IL-6RαT−KO mice were not available at this point.
Assessment of fibrosis which is often connected with the development of liver
cancer, revealed no significant alteration between the genotypes. Even upon
HFD feeding no significant alteration could be detected in IL-6RαL−KO and IL-
6RαM−KO mice compared to NCD feeding, contrary to IL-6Rα∆/∆ mice after HFD
feeding (Fig. 3.34D). HFD data of IL-6RαT−KO mice were not available at this
point.
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Figure 3.34: Liver status of control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-
6RαT−KO mice
(A) Quantitation of inflammation measured in the big liver lobe of DEN-
injected 8 mo control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO.
1 = mild inflammation (mild portal inflammation, 3-5 single cell necrosis, no
grouped necrosis); 2 = moderate inflammation (moderate portal inflamma-
tion, 6-9 single cell necrosis, 1 grouped necrosis); 3 = severe inflammation
(severe portal inflammation, more than 10 single cell necrosis, more than 1
grouped necrosis) (n=15). (B) Quantitation of steatosis measured in the big
liver lobe of DEN-injected 8 mo control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO
and IL-6RαT−KO. 1 = 0 - 10%; 2 = 11 - 50 %; 3 = above 50 % (n=15) (C) Quan-
titation of necrotic cells measured in the big liver lobe of DEN-injected 8 mo
control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO. (n=15) (D)
Quantitation of fibrosis measured in the big liver lobe of DEN-injected 8 mo
control, IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO. 1 = increased
portal connective tissue; 2 = early formation of septa (n = 15). Displayed val-
ues are means± S.E.M.; *, p≤ 0.05; **, p≤ 0.01; ***, p≤ 0.001 versus control.
Data produced in collaboration with Beate Straub.
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Regulatory T cells (Tregs) are the main regulators of the immune system. IL-
6 plays a crucial role in differentiation and activation of regulatory T cells and
it is known that different types of cancer are correlated with increased numbers
of Tregs which suppress the immune response and promote cancer development
[Haruta et al., 2011; Mougiakakos, 2011; Mougiakakos et al., 2010]. To investigate
weather Tregs play a role in the IL-6 dependent development of HCC, control,
IL-6Rα∆/∆ and IL-6RαT−KO mice were injected with 1 mg α-CD25 antibody i.p.
at 13 days of age to deplete Tregs in the initial phase of tumor development. As
before these mice were injected with 25 mg/kg BW DEN at 15 days of age i.p.
and exposed to NCD. Tumor investigation after 8 month revealed a duplication
of tumor number both in IL-6Rα∆/∆ and IL-6RαT−KO mice compared to control
mice suggesting a crucial role of Tregs in the IL-6 mediated development of HCC
(Fig. 3.35A). Collaboration with the lab of Ruslan Medzhitov indicated that IL-
6 signaling on effector T cells is necessary to release them from suppression by
Tregs. In this context natural killer like T cells (NKT cells) become the focus of
attention. To investigate the role of NKT cells, eight weeks old control, IL-6Rα∆/∆
and IL-6RαT−KO mice were injected i.p. with 4 µg αGalactosylceramide (αGalCer)
to specifically activate NK T cells and sacrificed at different time points. This
analysis revealed increased ALT and AST level in IL-6Rα∆/∆ and IL-6RαT−KO
mice upon αGalCer induction (Fig. 3.35B/C). To determine expression of IL-6Rα
specifically on NKT cells, activated NKT cells were analysed by Fluorescence-
activated cell sorting (Facs) analysis, revealing that maximum 2% of NKT cells
express the IIL-6Rα (Fig. 3.35D).
Taken together, these data demonstrate that IL-6Rα signaling in T cells play
an essentielle role whereas IL-6Rα signaling in hepatocytes and macrophages
is only minor involved in HCC development. In contrast, IL-6Rα signaling in
macrophages seems to be more important upon HFD feeding indicated by miss-
ing alteration of liver damage and inflammation upon HFD feeding.
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Figure 3.35: Turmor burden macroscopic in control, IL-6Rα∆/∆ and IL-6RαT−KO mice
(A) Quantitation of macroscopic tumor multiplicity determined by visual
inspection in DEN-injected 8 mo control, IL-6Rα∆/∆ and IL-6RαT−KO mice
(n=6) (B) Determination of serum AST (n=5) and (C) serum ALT activity to
assess liver damage in 8 wk control, IL-6Rα∆/∆ and IL-6RαT−KO mice fed on
a NCD sacrificed at the indicated time points after a 4 µg αGalCer injection
(n=5). (D) Facs analysis of NKT cells, gated for tetramer and IL-6Rα (n=4).
Data produced in collaboration with Christoph Vahl. Displayed values are
means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 versus control.
4 Discussion
HCC is the most common primary liver cancer worldwide with about 700.000
new cases per year [El-Serag & Rudolph, 2007]. Only 3-5 % of the patients survive
due to very limited treatment strategies. All main risk factors for HCC, such as
Hepatitis B/C and alcoholic or non-alcoholic steatohepatitis, cause liver damage
and chronic inflammation, characterizing HCC as a classic case of inflammation
linked cancer [Mantovani et al., 2008; Fattovich et al., 2004]. This chronic hepatic
inflammation leads to cell death and consequently to compensatory proliferation
of hepatocytes and ultimately to tumor development [Bisgaard et al., 1998].
Epidemiological studies identified HCC as the strongest obesity-associated can-
cer [Calle et al., 2003]. The excessive weight gain during obesity is associated with
a chronic low grade inflammatory state as a consequence of infiltrating immune
cells into the white adipose tissue (WAT) and the liver [Xu et al., 2003; Weisberg
et al., 2003; Olefsky & Glass, 2010]. During obesity, adipocytes rise in size and
increasing mechanical stress results in ruption and leakage of adipocytes and in
liberating of free fatty acids into circulation [Ferrante, 2007]. This in turn leads
to the recruitment and activation of immune cells, such as macrophages and T
cells, to the WAT. These immune cells release cytokines, such as TNFα and IL-6
[Nishimura et al., 2009; Xu et al., 2003; Hotamisligil et al., 1993].
Human studies could demonstrate that the concentration of IL-6 in serum is in-
creased in situations of chronic inflammation including alcoholic hepatitis, HBV
and HCV infections and steatohepatitis, conditions that may lead to development
of HCC [Abiru et al., 2006]. IL-6 concentrations are also increased in patients with
HCC compared to normal subjects, but whether IL-6 is causal or contributory to
HCC is still unknown [Soresi et al., 2006]. Recent studies in mouse models de-
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scribed a pivotal role of IL-6 in the development of chemical induced HCC but
the underlying mechanism is still poorly understood [Naugler et al., 2007].
In contrast to other studies, the current study used the conditional gene target-
ing to disrupt the IL-6Rα instead of IL-6 to examine the intracellular effect of IL-6
signaling in chemical induced HCC and the influence of obesity to this mecha-
nism. To adress this question, IL-6Rα f l/ f l (controls) and IL-6Rα∆/∆ mice were
injected with DEN to induce HCC development and were exposed to either NCD
or HFD feeding after weaning for 8 month.
Furthermore, conditional gene targeting has been applied to facilitate hepato-
cyte specific, myeloid specific and T cell specific disruption of the IL-6R to in-
vestigate the cell type specific role of IL-6 signaling in the development of HCC,
which would be not possible if IL-6 knock out mice would be used. Therefore, IL-
6Rα f l/ f l (controls), IL-6Rα∆/∆, IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO mice
were injected with DEN to induce HCC development and were exposed to either
NCD or HFD feeding for 8 month.
4.1 IL-6Rα deficiency protects against DEN-induced liver
carcinogenesis, but obesity abrogates this effect
The current study could demonstrate that IL-6Rα signaling promotes DEN-induced
liver carcinogenesis accompanied by increased inflammation. The macroscopic
tumor investigation in the current study could confirm that IL-6Rα-deficiency
upon NCD feeding protects against DEN induced HCC - a finding that was also
validated by pathological investigation [Naugler et al., 2007] . Moreover, fur-
ther pathological investigations of the tumor livers revealed decreased inflam-
mation and steatosis upon IL-6Rα-deficiency under NCD conditions, which is in
line with Naugler et al. [2007] findings. However, abrogation of IL-6Rα-signaling
did not decrease liver AST level after DEN treatment in contrast to earlier obser-
vations in IL-6-deficient mice [Naugler et al., 2007]. Also, the amount of necrotic
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cells in livers lacking the IL-6Rα upon NCD feeding were contradictory to pre-
vious results of Naugler et al. [2007]. While the authors postulate a decrease
in necrosis in IL-6-deficient mice, the current study revealed similar amounts of
necrotic cells in control and IL-6Rα∆/∆ mice upon NCD feeding.
Additional studies of HCC development demonstrate that HFD-induced obe-
sity increases DEN-induced HCC development in control mice which is in line
with earlier observations [Park et al., 2010]. Surprisingly, HFD feeding abro-
gates the protective effect of IL-6Rα deficiency on HCC development which is
in contrast to previous findings [Park et al., 2010]. The results of the current study
demonstrate that obesity abrogates the protective effect of IL-6Rα deficiency and
promotes HCC development by inducing inflammatory conditions mediated by
elevated levels of TNFα and IL-6.
Earlier studies described that spontaneously developed liver damage in Nemo/
IKKγ∆hep mice is promoted by HFD-feeding and results in tumor development
[Wunderlich et al., 2008]. Furthermore, Park et al. [2010] demonstrated recently
that both dietary- and genetically-induced obesity in mice increased HCC de-
velopment and progression in control mice compared to NCD-fed control mice.
This study demonstrated that HFD-induced increase in HCC development and
progression in control mice is a consequence of obesity-induced elevation of both
TNFα and IL-6. In line with these findings, the current study can also confirm
increased levels of TNFα and IL-6 in tumor livers upon obesity. Interestingly,
also upon IL-6Rα deficiency HFD feeding leads to an increase of TNFα and IL-6
in the tumor livers, underlining the differences in tumor development between
IL-6- and IL-6Rα-deficiency. Further investigation of inflammatory status of the
liver revealed increased liver damage reflected by increased liver AST level af-
ter DEN treatment but no differences between genotypes or diets in contrast to
earlier observations [Park et al., 2010]. Moreover, pathological analysis of tumor
livers of the different cohorts revealed increased inflamm=ation upon HFD feed-
ing, which was also demonstrated by Park et al. [2010]. Differences between IL-6-
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and IL-6Rα deficiency turn up again in inflammatory status, demonstrated by
increased inflammation also in IL-6Rα-deficient livers upon HFD feeding. How-
ever, the number of necrotic cells and the existing fibrosis were increased upon
HFD feeding.
Taken together, there is a differential effect of previously described IL-6 defi-
ciency versus the results on IL-6Rα deficiency in obesity-induced HCC develop-
ment. Both IL-6 and IL-6Rα deficiency in lean mice protect against HCC devel-
opment, whereas in the obese state IL-6Rα∆/∆ mice exhibit similar tumor num-
bers as control mice but IL-6 knock out mice fail to develop HCC under these
conditions [Park et al., 2010]. In line with these reported differential effects, a
recent publication demonstrated a similarly different experimental outcome in
IL-6- and IL-6Rα-deficient mice when addressing the function of IL-6 in wound
healing [McFarland-Mancini et al., 2010]. While IL-6-deficient mice demonstrated
greatly reduced wound healing capacity, IL-6Rα deficiency showed only slightly
impaired wound healing. Further analysis of IL-6Rα and IL-6 double knock out
mice revealed that IL-6Rα deficiency dominated wound healing capacity. Thus,
these studies and the latest findings point towards a more complex role of IL-6Rα
signaling in inflammatory processes than assumed so far.
4.2 Similar extent of obesity in control and IL-6Rα∆/∆ mice in
the DEN-induced HCC model
One explanation for the different outcome of HCC incidence between IL-6 and
IL-6Rα deficient mice could be an altered influence of HFD feeding to these mice.
However, the current study demonstrated that control and IL-6Rα∆/∆ mice re-
vealed no differences concerning glucose and fatty acid metabolism and that HFD
exposure causes similar levels of obesity in both control and IL-6Rα∆/∆ mice upon
DEN induction. Moreover, HFD feeding results in IL-6 resistance in control mice
resulting in impaired Stat-3 activation.
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Investigation of glucose metabolism revealed no alterations in body weight
and blood glucose clearance, which is surprising in reference to previous studies
which revealed an impaired glucose metabolism in mice with impaired IL-6Rα
signaling in hepatocytes [Wunderlich et al., 2010]. Hepatic insulin resistance as
a consequence of HFD feeding leads to a diminished suppression of hepatic glu-
cose production and thus exhibits a crucial impact on the impairment of whole
body glucose metabolism [Li & Yang, 2004]. IL-6 signaling plays an important
role in the development of hepatic insulin resistance during obesity and previ-
ous observations revealed that IL-6 treatment increases glucose tolerance in rats
[Holmes et al., 2008; Klover & Mooney, 2004; Senn et al., 2002]. However, no ef-
fects of L-6Rα deficiency could be detected in the current study.
The Insulin levels in the current study revealed no difference between control
and IL-6Rα∆/∆ mice upon both NCD and HFD feeding. In contrast to that, Park
et al. [2010] could demonstrate decreased Insulin levels upon IL-6-deficiency af-
ter HFD feeding. Furthermore, the decreased triglyceride levels in IL-6 deficient
mice upon HFD feeding, could not be observed in IL-6Rα deficient mice in the
current study. No differences could be observed in fatty acid metabolism, mea-
sured by circulating cholesterol or triglycerides, as well as lipid accumulation in
the liver.
IL-6 initiates downstream signaling by binding to the IL-6 receptor (IL-6R)
whose activation results in multiple downstream signaling events in the liver
such as activation of the JAK/Stat-3 pathways Heinrich et al. [2003]. Treatment of
control mice with IL-6 revealed a robust Stat-3 phosphorylation in the liver. In-
terestingly, HFD feeding leads to an diminished Stat-3 activation in the liver sug-
gesting an impaired responsiveness to acute IL-6 stimulation as a consequence
of obesity. Recent studies could demonstrate that chronically raised IL-6 levels
in obesity could cause Insulin resistance and IL-6 resistance [Wunderlich et al.,
2013]. This may involve basal increase of Socs protein levels in peripheral or-
gans, such as the liver, similarly to the findings described for basal leptin-derived
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signal transduction in the CNS [Wunderlich et al., 2013].
4.3 Obesity and IL-6 increase HCC development through the
inhibition of mitochondrial apoptosis
Increased IL-6 levels under inflammatory conditions and in obesity were pre-
dicted to inhibit hepatocyte apoptosis, a driving force in DEN-induced HCC de-
velopment [Park et al., 2010]. The current study could demonstrate that under
NCD conditions, loss of IL-6 signaling sensitizes hepatocytes to damage-induced
apoptosis by decreased protein levels of anti-apoptotic Bcl-2 protein family mem-
ber Mcl-1 at the mitochondria without impairments in compensatory prolifera-
tion. However, under HFD conditions, hepatocyte apoptosis is inhibited – even
in the absence of IL-6Rα signaling.
Investigation of hepatocyte apoptosis in the DEN-induced HCC model revealed
that IL-6Rα∆/∆ mice, which have decreased tumor development, display increased
Caspase 3 activity upon NCD feeding which is in line with induction of Caspase
3 as a potent cancer therapy [Tatsukawa et al., 2011]. Furthermore, after acute
induction with DEN, an increased Caspase 3 cleavage could be observed, trans-
lating into an increase of liver AST levels, which reflects liver damage. These
effects were completely blunted upon HFD feeding, which was also reflected in
abrogated tumor protection in IL-6Rα∆/∆ mice.
Mitochondria represent a central sensory organelle that can respond to DNA
damage by outer membrane permeabilization. The current study revealed that
increased Caspase 3 activity in IL-6Rα∆/∆ mice upon NCD feeding is a conse-
quence of enhanced mitochondrial apoptotic response, demonstrated by elevated
release of Cytochrome C from isolated mitochondria after Bax treatment. Consis-
tently, IL-6Rα-deficient hepatocytes demonstrated concentration dependent cy-
tosolic Cytochrome C levels in response to DEN as well as increased Cytochrome
C at the mitochondria itself. The increased hepatic apoptosis sensitivity of lean
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IL-6Rα-deficient mice is due to a decrease of anti-apoptotic protein Mcl-1. This
effect is completely abolished under HFD conditions, which is reflected in the ab-
rogated protection from tumor development in IL-6Rα-deficient mice upon HFD
feeding. Notably, protein levels of other Bcl-2 family members were only slightly
altered betweens diets and genotypes.
The balance between anti- and pro-apoptotic members of the Bcl-2 protein fam-
ily regulates mitochondrial outer membrane permeabilization and the efflux of
Cytochrome C in response to cellular damage [Brunelle & Letai, 2009]. One of
these anti-apoptotic proteins is Mcl-1 which keeps Bak and Bax separated at the
outer membrane of the mitochondria [Tait & Green, 2010; Maurer et al., 2006].
After phosphorylation Mcl-1 is ubiquitinated and degraded, Bax and Bak can as-
semble which leads to the release of Cytochrome C, activation of caspases and
eventually to apoptosis [Tait & Green, 2010; Maurer et al., 2006]. Immunohisto-
chemistry of mouse liver sections and western blot analysis of dissected HCCs
underlined the finding that Mcl-1 protein is decreased in HCCs of lean IL-6Rα-
deficient mice compared to controls, while HFD feeding significantly increased
Mcl-1 protein abundance in HCCs of control as well as IL-6Rα∆/∆ mice indepen-
dent from IL-6Rα signaling.
Strikingly, qPCR analyses of the Bcl-2 family members revealed largely unal-
tered transcriptional levels of the corresponding genes suggesting that the re-
duced Mcl-1 content at the mitochondria of IL-6Rα∆/∆ mice might be caused by a
posttranslational regulatory mechanism. This results are contrary to earlier find-
ings that Mcl-1 expression is increased in HCC [?].
Along this line, previous studies have clearly demonstrated that Mcl-1 is an
anti-apoptotic factor for a subset of human HCC, whose inhibition might have
potential in human therapy, but may also result in liver damage and cancer de-
velopment [Weber et al., 2010; Vick et al., 2009; Fleischer et al., 2006; Schulze-
Bergkamen et al., 2006]. It has been previously demonstrated that hepatocyte-
specific Mcl-1 inactivation causes spontaneous HCC in old mice as a consequence
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of a microenvironment comprising apoptosis sensitive Mcl-1-deficient hepato-
cytes and compensating adjacent hepatocytes [Weber et al., 2010]. Of note, HCC
development in these mice occurs in the absence of chronic inflammation. The
current DEN-induced HCC model depends on inflammation and high Mcl-1 pro-
tein levels. Moreover, the current study could demonstrate that DEN-induced
compensatory proliferation of hepatocytes was comparable between control and
IL-6Rα∆/∆ mice. Interestingly, Bak protein level are slightly decreased in IL-
6Rα∆/∆ mice upon NCD feeding, which are protected against HCC. This result
is underlined by the recent finding that the compound inactivation of Mcl-1 and
BAK not only normalizes apoptosis sensitivity of hepatocytes but also prevents
liver cancer development [Hikita et al., 2012].
4.4 GSK-3β inhibition stabilizes Mcl-1 via IL-6 signaling and
under obese conditions in HCC development
The current study could demonstrate that IL-6Rα-deficiency decreases Mcl-1 pro-
tein levels at the mitochondria without decreasing transcription, suggesting a
posttranslational regulation of Mcl-1 within tumor lesions. The present work
could provides evidence that GSK-3β action increases the hepatic Mcl-1 turnover
rate in IL-6Rα deficiency, thereby decreasing Mcl-1 protein levels. Furthermore,
it could be demonstrated that GSK-3β inactivation by phosphorylation at S9 is
required to stabilize Mcl1 during the initial phases of tumorigenesis
Unlike other Bcl-2 family members, Mcl-1 has a dynamic turnover rate [Mau-
rer et al., 2006; Kozopas et al., 1993]. While Mcl-1 expression at the transcrip-
tional level depends on PI3K-mediated signal transduction as well as IL-6-evoked
signaling, the dynamic turnover rate of Mcl-1 is controlled by GSK-3β [Maurer
et al., 2006; Jourdan et al., 2003; Epling-Burnette et al., 2001a,b]. Mcl-1 comprises
a N-terminal proline, glutamic acid, serine, threonine peptide sequence (PEST
domain), which is responsible for its short half-life. Phosphorylation of Mcl-1
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in the PEST domain by GSK-3β leads to its polyubiquitination and subsequent
proteasome-mediated degradation, which initiates apoptosis [Maurer et al., 2006].
Investigation of GSK-3β in the current study revealed a remarkable decrease of
phosphorylation in livers of IL-6Rα∆/∆ mice upon NCD feeding, also reflected by
decreased Mcl-1 protein levels which leads to increased mitochondrial apoptosis
und subsequently to decreased tumor numbers. Moreover, in line with the stabi-
lized Mcl-1 levels in IL-6Rα∆/∆ mice upon HFD feeding, GSK-3β phosphorylation
is also restored. Consistent with these findings, direct assessment of GSK-3β ac-
tivity revealed a significant increase of activity in lean IL-6Rα∆/∆ mice, an effect
which is abrogated upon HFD feeding. Direct proof about the role of GSK-3β
regarding Mcl-1 stabilization in vivo, is provided by the injection of an adeno-
associated virus containing a constitutive active GSK-3β variant (GSK-3βCA) in
control mice. This GSK-3βCA reduces Mcl-1 protein level in the liver to a similar
extent as in IL-6Rα∆/∆ mice.
Active GSK-3β has been previously reported to regulate apoptosis through ex-
pression of the BH3 only member PUMA that antagonizes Mcl-1 to sensitize for
apoptosis [Charvet et al., 2011]. Investigation of PUMA expression in IL-6Rα∆/∆
mice revealed 2-fold increase compared to control mice which is restored under
obese conditions. However, in the initial phase of tumor development PUMA
expression is unchanged between genotypes. Moreover, PUMA protein level
peaked in both genotypes 24h after DEN injection, indicating a GSK-3β indepen-
dent mechanism controls PUMA expression under these conditions. This become
even more clear by the fact that PUMA levels failed to correlate with GSK-3β ac-
tivity under acute DEN conditions.
The regulation of GSK-3β is controlled at multiple levels and its misregulation
is known to contribute to the development of numerous diseases such as dia-
betes, Alzheimer’s disease, and cancer [Patel & Woodgett, 2008; Eldar-Finkelman
et al., 1999; Eldar-Finkelman & Krebs, 1997; Hanger et al., 1992]. GSK-3β is a ser-
ine/threonine protein kinase that is constantly active. Inactivation of GSK-3β by
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phosphorylation at serin residue 9 (S9) increases stabilization and accumulation
of Mcl-1 and therefore prevents apoptosis [Ding et al., 2007]. GSK-3β S9 phospho-
rylation mainly occurs through the action of Phosphatidyli- nositide 3-kinases
(PI3K) signaling as a substrate of AKT phosphorylation in response to insulin
[Cross et al., 1995]. The current work revealed that PI3K/AKT signaling is active
but not altered in IL-6Rα∆/∆ mice during HCC development independent from
dietary conditions. Determination of the role of PI3K signaling in DEN-induced
HCC development of HFD fed mice by treating HCC-bearing HFD fed control
mice with a PI3K inhibitor resulted in reactivation of GSK-3β leading to reduced
levels of Mcl-1. This reduction of Mcl-1 transfers into increased number of apop-
totic cells and a reduced proliferation in the liver of mice with inhibited PI3K.
This results are in line with previous studies, demonstrating that the PI3K/AKT
pathway transmits anti-apoptotic survival signals and is likely involved in mit-
igating apoptosis in a substantial fraction of human tumors [Jiang & Liu, 2008;
Cully et al., 2006]. Despite all that, the formation of PIP3 was similar between
diets and genotypes. Even the activity of downstream kinases such as PDK and
AKT were unaltered between diets and genotypes indicating the contribution of
another factor which regulates GSK-3β activity.
4.5 Obesity and IL-6 controlled expression of PP-1α and
Mule synergize to stabilize Mcl-1
The current study demonstrated that activation of PI3K/AKT signaling is not al-
tered between diets and genotypes. Therefore, another regulatory element must
be responsible for the differences in GSK-3β activity between diets and geno-
types. Protein phosphatase 1 α (PP-1α) catalyzes the reverse reaction, namely
GSK-3β dephosphorylation at S9. Investigation of PP-1α expression level re-
vealed a 2-fold increase in IL-6Rα-deficient mice upon NCD feeding, an effect
which is completely blunted after HFD feeding. This increase in expression level
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is due to decreased Stat-3 activation, which acts as a suppressor on the PP-1α
promoter, demonstrated by ChIP analysis of the PP-1α promoter.
Transcriptional control of IL-6 regulated genes mainly occurs via the transcrip-
tion factor Stat-3. Several studies demonstrated a key role of Stat-3 in cancer
development. Grivennikov & Karin [2008] demonstrated a constitutive Stat-3 ac-
tivation in different types of cancer. Furthermore, increased Stat-3 activity was
found in chemical induced HCC in rats, indicating an essential role of Stat-3 in
the formation of HCC [Sánchez et al., 2003]. If activation of Stat-3 is inhibited, pro-
liferation of HCC cells is suppressed, which is associated with increased apopto-
sis, cell arrest, reduced proliferation and inhibited expression of growth factors
[Sun et al., 2008; Li et al., 2006]. In consequence, expression of Stat-3- regulated
genes including B-cell lymphoma extra large (Bclxl), Cyclin D1 and c-Myc, which
are involved in apoptosis and cell cycle progression, were downregulated [Sun
et al., 2008]. Interestingly, tumor cells use IL-6 to constitutively activate Stat-3
whereas other cytokines like IL-11 or IL-22 could also provoke Stat-3 phospho-
rylation and tumor development. One consideration is that inflammatory cells
in close interaction to cancer cells can produce big amounts of “start-up” IL-6
which is required for early tumor production. IL-6 seems to have a dual role in
the development of chemically induced HCC. At first, IL-6 advances cell injury
and later the compensatory proliferation of hepatocytes. Secondly, IL-6 provides
growth signals to transformed hepatocytes [Grivennikov & Karin, 2008].
However, PP-1α inhibition by the inhibitor ocadaic acid is not sufficient to sta-
bilize Mcl-1 protein level, suggesting another synergistic pathway independent
from PP-1α. These data confirm that IL6Rα-deficiency increases PP1α expression
that regulates GSK-3β activity, but it is not sufficient to reduce Mcl-1.
While the current study clearly demonstrate that PI3K/AKT action is not im-
paired in the absence of IL-6Rα signaling, the experiments reveal a critical role
of IL-6 signaling in the control of PP-1α expression. However, while S9 phos-
phorylation dependent control of GSK-3β activity was shown to regulate Mcl-1
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protein stability, GSK-3β action requires pre-phosphorylation of Mcl-1 in order
to exert its regulatory function [Morel et al., 2009; Maurer et al., 2006]. Never-
theless, the experiments revealed a correlation between GSK-3β phosphorylation
and Mcl-1 protein stability in this mouse model. However, at this point it cannot
be excluded that, depending on dietary conditions, IL-6Rα signaling in addition
to GSK-3β regulation also controls the activity of additional Mcl-1 kinases, such
as ERK or JNK. In line with this notion, previous studies have suggested that
MAPK/ERK and JNK-dependent phosphorylation of Mcl-1 may also decrease
Mcl-1 stability [Morel et al., 2009; Kodama et al., 2009; Domina et al., 2004]. Fur-
thermore, increased and sustained JNK-1 activity, as observed in obesity and dur-
ing DEN-induced HCC development, can stabilize Mcl-1 [Kodama et al., 2009;
Hui et al., 2008; Hirosumi et al., 2002].
Recently, GSK-3β-phosphorylated Mcl-1 has been shown to be recognized by
either Mule or the SCFFBW7 E3 ligase both of which ligate polyubiquitin chains
to Mcl-1 that lead to its proteasomal degradation [Wertz et al., 2011; Zhong et al.,
2005]. Determination of the expression of these E3 ligases in the current study
displayed a correlation of Mule expression with Mcl-1 levels in lean and obese
control and IL-6Rα∆/∆, whereas expression of the subunits FBW7 and cullin-1 of
the SCF complex revealed only a minor expression in HCC. Promoter analysis
of the Mule promoter could demonstrate that Mule expression is a direct target
of IL-6-mediated Stat-3 repression which could be proven both in vivo by using
mice with a constitutive active Stat-3 as well as in vitro by a Luciferase assay and
ChIP analysis. These data clearly prove that expression of ubiquitin ligase Mule is
directly regulated by IL-6 mediated Stat-3 activation in the development of HCC.
Interestingly, while the increased tumor burden in obese mice in the current
study was accompanied with increased Mcl-1 levels in tumor lesions indepen-
dent of IL-6Rα signaling, the severity of tumor specific lipid accumulation in
human HCC positively correlated with Mcl-1 abundance [Fleischer et al., 2006].
Moreover, the current work could demonstrate a negative correlation between
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Mcl-1 and Mule levels in human HCC, indicating this mechanism as translational
to human disease.
4.6 Obesity promotes liver carcinogenesis via Mcl-1
stabilization independent of IL-6Rα signaling
Considering the insights from the current work, the following model has the abil-
ity to clarify the role of IL-6 signaling in the development of HCC.
In lean control mice IL-6 decreases apoptosis sensitivity through Stat-3 acti-
vation and Mcl-1 stabilization. Stat-3 activation controls the synergistic actions
of GSK-3β via inhibition of PP-1α expression and Mule via its inhibition which
results in HCC development. Accordingly, IL-6Rα-deficiency release PP-1α and
Mule expression from Stat-3-mediated inhibition, leading to an increased apop-
tosis sensitivity in hepatocytes. This sensitivity is caused by Mcl-1 degradation
mediated by active GSK-3β and Mule which protects against DEN-induced HCC.
In contrast in obesity, DEN-induced HCC development and progression oc-
curred even in the absence of IL-6Rα expression as a consequence of obesity-
induced GSK-3β inhibition and transcriptional repression of Mule leading to Mcl-
1 stabilization. Along these lines, inhibitory S9 phosphorylation of GSK-3β was
increased upon HFD feeding both in control and IL-6Rα∆/∆ mice, whereas Mule
and PP-1 α expression was significantly inhibited under obese conditions not only
in control but also in IL-6Rα-deficient animals.
Therefore in lean mice, IL-6 appears to be the critical regulator of GSK-3β as
well as Mule-inhibition, while alternative signals may control these molecules in
obese mice.
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Figure 4.1: Model of apoptosis-regulation in HCC via IL-6 signaling and obesity
(A) IL-6 signaling activates Stat-3 which inhibits PP-1α and Mule expression.
(B) Since PP-1α can not dephosphorylate GSK-3β, phosphorylation at S9 by
AKT inhibits GSK-3β action which leads to stabilization of Mcl-1. (C) Mcl-
1 keeps Bax and Bak seperated at the mitochondria which prevents release
of Cytochrom C and inhibits apoptosis. (D) Under obese conditions Stat-3-
mediated inhibition of PP-1α and Mule expression occurs independent from
IL-6 signaling. Picture produced with the help of Justus Ackermann.
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4.7 Inactivation of gp130 in hepatocytes protects against
DEN-induced HCC development even under obese
conditions
Apparently, the experiments refer to a not yet identified factor that compen-
sates for IL-6Rα deficiency in obesity-associated HCC development. In the pro-
inflammatory state in obesity this factor could be increased, thereby elevating
basal hepatic Stat-3 activation, but impairing acute responsiveness. Evidently, not
only the restored hepatic Stat-3 activation in obese IL-6Rα∆/∆ mice occured inde-
pendent of IL-6 but also the remaining DEN-induced Stat-3 activation in lean IL-
6Rα∆/∆ mice, thus indicating another obesity- and/or DEN-induced factor that
activates Stat-3 in the absence of IL- 6Rα.
While it is certainly not clear which factor in obesity compensates for IL-6Rα
deficiency in HCC development, another IL-6 type cytokine or receptor might
account for this observation. The common feature of all IL-6 type cytokine recep-
tors is the signaling transducing receptor unit glycoprotein 130 (gp130) [Zhang
et al., 1994]. Although, determination of HCC development in hepatocyte spe-
cific gp130-deficient mice revealed a protection against DEN induced HCC even
under obese conditions, investigation of IL-6 type cytokines and receptors expres-
sion in tumor livers of control and IL-6Rα deficient mice under both dietary con-
ditions failed to directly clarify which factor compensates for IL-6Rα deficiency
in HCC development upon HFD feeding. However, other signaling pathways,
such as Leptin signaling, use Stat-3 to initiate gene expression [Yang & Barouch,
2007]. Indeed, Leptin levels in IL-6Rα deficient mice upon HFD feeding are even
more increased than levels in control mice. Moreover, pilot experiments revealed
an increase in Leptin receptor expression in IL-6Rα deficient mice after HFD feed-
ing, indicating an unknown role of Leptin signaling in the development of HCC.
Though, the role of Leptin in liver carcinogenesis has to be further elucidated.
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4.8 IL-6RαT−KO mice are protected against DEN-induced
HCC even on HFD
The tumormicroenvironment, especially the infiltrating immune cells play a ma-
jor role in the development of cancer. In HCC development infiltrating immune
cells create a tumor microenvironment releasing elevated levels of pro-inflammatory
cytokines such as TNFα and IL-6, both of which are tumor-promoting cytokines
[Newell et al., 2008; Lin & Karin, 2007; Xu et al., 2003]. In the liver these IL-6 levels
can be recognized by hepatocytes, macrophages and T cells which all express the
IL6Rα.
The current work could demonstrate that IL-6Rα signaling on T cells has a piv-
otal role in the development of HCC, whereas IL-6Rα deficiency on hepatocytes
has only minor effects on liver carcinogenesis.
Investigation of IL-6RαL−KO, IL-6RαM−KO and IL-6RαT−KO mice in a DEN-
induced HCC approach revealed no differences in tumor development in IL-
6RαL−KO and IL-6RαM−KO mice compared to control mice whereas IL-6RαT−KO
mice are protected against DEN-induced HCC even upon HFD feeding indicat-
ing that IL-6 signaling on T cells promotes HCC development.
The CD4 cre construct which is used for the IL-6RαT−KO consists of the CD4
promoter, the Cre gene and a Poly A. The silencer from the CD4 is excised re-
sulting in Cre expression in CD4+, CD8+ and NKT cells. IL-6 plays a pivotal
role in differentiation and activation of different T cell subsets such as TH17 and
regulatory T cells (Tregs) [Bettelli et al., 2006]. Moreover it is known that IL-6 sig-
naling deficient mice have an impaired TH17 differentiation and that IL-6 is re-
quired to overcome Tregs mediated suppression [Haruta et al., 2011; Pasare, 2003].
Although, previous studys could observe an increase in Tregs in different types
of cancer, such as pancreatic cancer or colorectal cancer [Mougiakakos, 2011;
Mougiakakos et al., 2010; Beyer, 2006; Wolf et al., 2003], depletion of Tregs dur-
ing the initial phase of HCC development doubled tumor number in IL-6Rα∆/∆
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and IL-6RαT−KO mice compared to mice with Tregs.
Collaboration with Ruslan Medzhitov suggested that IL-6Rα signaling on effec-
tor T cells is required to overcome repression by Tregs [personal communication].
Considering that HCC is an inflammation-linked cancer with increased levels of
TNFα and IL-6 and that obesity increases HCC in this model, NKT cells could be
a potential candidate for the crucial cell type concernig IL-6 signaling in HCC.
NKT cells are a subset of T cells often found in the liver [Swain, 2008]. It
has been previously reported that NKT cells are associated with with liver in-
jury and inflammation [Gao et al., 2009]. They express the inhibitory NK cell
receptor NK1.1 and the semi-invariant T cell receptor Va14Ja18 [Harada et al.,
2004; Vivier & Anfossi, 2004]. This T cell receptor binds lipids and ceramides
leading to crosslinking of the TCR receptor which results in an inflammatory re-
sponse with release of TNFα and IL-6 [Gao et al., 2009]. The endogenous ligand
of the TCR receptor is still unknown but binding of α Galactosylceramide, a lipid
of a marine sponge, leads to hepatic injury and release of TNFα and IL-6 [Van
Der Vliet et al., 1999]. Although, activation of NKT cells in control, IL-6Rα∆/∆ and
IL-6RαT−KO mice by αGalCer mediates an increase liver damage in IL-6Rα∆/∆
and IL-6RαT−KO mice, only a very small fraction of NKT cells could be detected
which express the IL-6Rα.
IL-6-stimulation of primary hepatocytes and human liver tumor cells to verify
the mechanism of Mcl-1 stabilization in HCC in vitro, revealed a less potent effect
than observed in vivo indicating another factor which could contribute to inhi-
bition of apoptosis by stabilizing Mcl-1. Therefore, the question raises weather
there is another factor which contributes to the inhibition of hepatocyte apopto-
sis in HCC, which could be released by activated T cells.
Since the repression of Mule and PP-1α expression by activated Stat-3 could
be shown in vivo and in vitro, another synergistic pathway, which uses Stat-3 as
signal transducer, could be involved in the observed effects. Considering that
Dominik Schenten from the group of Ruslan Medzhitov could demonstrate that
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L-6Rα signaling on effector T cells is required to overcome Tregs-mediated sup-
pression, a signal from activated effector T cells could be in part responsible for
the Stat-3-mediated inhibition of apoptosis in hepatocytes [personal communica-
tion]. One potential candidate for this signal could be Interleukin 22. IL-22 is a
cytokines released by activated effector T cells, whose receptor is expressed on
hepatocytes [Rutz et al., 2013]. Radaeva et al. [2004] could demonstrate that IL-22
has a protective effect in T cell-mediated hepatitis in mice. This effect is mediated
by Stat-3 activation which serves as a survival factor for hepatocytes. Therefore,
IL-22 could be a potential candidate to inhibit Stat-3-mediated inhibition of apop-
tosis in hepatocytes, together with IL-6.
4.9 Conclusion
Collectively, this study has clearly identified IL-6- and obesity-induced Mcl-1 sta-
bilization as a critical factor for HCC development and progression. Moreover,
this study provides evidence that under obese conditions IL-6Rα-dependent reg-
ulation of GSK-3β and Mule is compensated for by an alternative mechanism,
which has to be further elucidated.
Moreover, it could be demonstrated that IL-6Rα signaling on T cells has a piv-
otal role in the development of HCC, which might be mediated by another cy-
tokine released from activated T cells.
Thus, the current work has strong implications for current translational re-
search on HCC and the development of novel therapeutic strategies aiming at
reactivating the mitochondrial apoptotic pathway under inflammatory and obese
conditions.
Therefor,e the current study implicate the provided mechanism as translational
to human disease in the light of increasing obesity in western countries.
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